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                                                 ABSTRACT 
  Carcinoma of uterine cervix is the most prevalent cancer among Indian women. 
The HER-2/neu is the Human epidermal growth factor receptor-2 and it is a gene 
localized on chromosome 17q21 that encodes a growth factor receptor like 
molecule with tyrosine kinase activity and has a structure similar to that of 
epidermal growth factor receptor. Its expression has been detected in several 
human cancers and is believed to be associated with poor prognosis, aggressive 
biological behavior and metastatic potential. The present study is to evaluate the 
presence of HER-2/neu in carcinoma cervix, its pattern of expression and 
correlation with histological type, grade of tumor and clinical stage. IHC is an 
excellent technique to detect HER-2/neu expression in carcinoma cervix.                           
Several studies on uterine lesions suggest HER2 positivity is directly  related with 
higher grade and more aggressive tumor, and  having poor prognosis. This study 
included 100 cases of carcinoma cervix and these were subjected to 
immunohistochemical staining for HER-2/neu oncoprotein. Out of 100 cases , only  
17 cases were found to be positive for HER-2/oncoprotein. Among these 17 cases, 
16 cases(94.1%) were of squamous cell carcinoma and 1 case was small cell 
carcinoma.It was also observed that the positivity rate varied  with differentiation 
and staging, lymphnode metastasis and parametrial extension status. Poorly 
differentiated squamous cell carcinoma showed 25% positivity, whereas positivity 
rate was 33.33% in cases of small cell carcinoma and was 50 % in stage III 
carcinoma. Also there was positivity rate of 33.33% in parametrial extension cases 
and 55% of positivity in lymph node metastatic cases. Thus HER-2/neu expression 
in Carcinoma cervix correlates with clinical stage, lymph node metastasis, and 
parametrial extension. 
KEYWORDS: Carcinoma cervix, IHC, HER-2/neu 
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INTRODUCTION 
Carcinoma of uterine cervix is the most prevalent cancer amongst 
Indian females 
(1)
.
   
In the developing countries, the most common cause of 
cancer mortality among female population is due to carcinoma cervix. 
Cervical carcinoma is the second most frequent malignancy in women 
worldwide. It is the major health problem, faced by the women in 
reproductive age group 
(2)
.The annual incidence of cervical carcinoma is 
about 1,32,000 and mortality caused by it is about 74,000
(3)
.Among the total 
number of cases in the world, Indian females contribute  to about one fourth 
of cases.  
The carcinoma cervix has histopathologically, well characterized 
precursor lesions (CIN), which slowly progresses to the well differentiated 
tumor. This transformation of cervical epithelial cells from CIN to 
carcinoma takes 10 – 15 yrs. During this transformation period , many 
important markers of tumor progression, are expressed. Thus carcinoma 
cervix, because of its long period of transformation,   provides a great 
opportunity to study about the expression of biomarkers of tumor 
progression. Because of the above advantages, present study was designed to 
evaluate the expression pattern of  HER2 neu ,in different grades of cervical 
precancerous lesion and cancer lesions to understand the role of HER2 neu 
in cervical carcinogenesis.  Many researches are going on to investigate the 
role of oncogenes in the development of cancers and the prognosis of various 
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cancers. The development of cancer depends on multiple factors and this 
process includes the sequential activation of oncogenes and other genetic 
derangements.
 [4]. 
The c-erbB-2 proto-oncogene is also called neu and HER-
2/neu gene. It is a gene localized on Chromosome 17q21 that encodes a 
growth factor receptor-like molecule with tyrosine kinase activity. It has a 
structure similar to that of epidermal growth factor receptor.
(5,6,7)
 Several 
tumors express  HER2 neu  and their expression has been associated with 
poor prognosis, aggressive behavior and its metastatic potential
(8)
 . The 
present study was conducted to evaluate the presence of HER2/neu in the 
tumors of uterine cervix, its pattern of expression and correlation with 
histological type, grade of tumor and clinical stage, wherever possible. 
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AIM OF THE STUDY 
1) To evaluate the expression of HER-2/neu oncogene  in the  Invasive 
carcinoma of uterine cervix  
2) To determine the correlation of HER2/neu expression with clinical 
stage of carcinoma cervix   
3) To determine the correlation of HER2/neu expression with  
histological  types and grades of carcinoma cervix.  
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REVIEW OF LITERATURE 
CARCINOMA CERVIX : 
EPIDEMIOLOGY: 
Cervical cancer is one of the most common cancers among women 
worldwide (WHO 2009).  Majority of cervical cancer cases today occur in 
the developing world. According to National Cancer Registry of ICMR the 
incidence in India is 14.42/100000 population with mortality rate 
2.83/100000 population (ICMR 2004). The highest incidence rates were 
observed in Latin America and the Caribbean, sub-Saharan Africa, and south 
and south-east Asia. Before the introduction of screening programmes, the 
incidence of cervical carcinoma was higher in Europe , North America and 
Japan over past several decades. 
The incidence rate  have declined in both white and African American 
women, for the past few decades. Since 2004 ,rates have decreased by 2.1 % 
per year in women younger than 50 years of age and by 3.1% per year in 
women aged 50yrs and above(American Cancer Society,Cancer Facts & 
Figures  2012).The demography based risk factors include age, marital 
status, socioeconomic status and ethnic and religious groupings. 
Cervical cancer is the first human cancer to be found to have 
infectious agent as a causative factor(Thomson et al 2008.). Among  the  risk 
factors of cervical cancer, human papilloma virus infection especially ,the 
high risk type of HPV and persistence of HPV infection is the most 
5 
 
important risk factor.  Harald Zur Hausen was awarded the noble prize in 
2008, for the discovery of HPV as a cause of cervical cancer. 
Human papilloma virus have nearly about 150 types.  Among these 
150 types, they are classified into high risk type, probable high risk, and low 
risk.  
• Nearly 15 types are classified as high-risk types -16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 
• 3 types as probable high-risk- 26, 53, and 66 
• 12 types as low-risk - 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 
(Walboomers, J.M et al  1999). 
• Types 16 and 18 cause about 70% of cervical cancer . Together 
with type 31, they are the prime risk factors for cervical cancer 
(Munoz N ,et al .,2003).HPV infections of the cervix is of transient 
in nature. This transient infection triggers immune system and 
produce immune response, mainly cellular immunity. Cellular 
immunity is responsible for the regression of HPV infections. In 
few cases the viral replication is prevented and may lead to latent 
infection or this will turn into active infection when the immune 
status of the patient is compromised. Certain factors like 
immunosuppression, high parity, smoking, long term use of oral 
contraceptive pills may accentuate the HPV infection to cancer 
(American Cancer Society , Cancer Facts & Figures).      
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Human papilloma virus usually infects immature squamous cells 
rather than mature cells. In cervix, the immature cells are seen in basal layer, 
where there is a break in the epithelium, and also seen in metaplastic 
squamous epithelium present at squamo-columnar junction. So HPV infects, 
most commonly the squamo-columnar junction where there is immature 
metaplastic cells. Even though it infects immature squamous cells, they 
replicate in the mature squamous cells. Due to their replication , there is a 
cytopathic effect in the mature cells and is called as ‘koilocytic atypia’. The 
koilocytic atypia is characterized by perinuclear vacuolation, dense- and 
irregular-staining peripheral cytoplasm, and an enlarged nucleus with an 
undulating (raisin- or prune-like) nuclear membrane and a rope-like 
chromatin pattern (Lee KR et al 1997),that is seen in the HPV infected 
mature superficial cells. Normally the mature superficial cells do not 
proliferate. Human papilloma virus ,in order to replicate in this 
nonproliferating squamous cells,they have to reactivate the mitosis. This is 
done  by interfering with the function  of Rb and P53 . Viral E6 /E7 proteins 
are critical for the oncogenic effect of HPV. (Schiffman M et al 2007). 
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EMBRYOLOGY: 
          The paramesonephric duct or the mullerian duct, which are formed by 
the invaginations of coelomic epithelium is responsible for genesis of uterus 
with cervix and the upper portion of vagina. 
ANATOMY: 
The uterus is divided into the corpus, isthmus, and cervix. The inferior 
most portion of uterus is the cervix and it protrude into the upper part of 
vagina.It is a fibromuscular organ  lined by mucus membrane. The length of 
cervix varies from 2.5–3 cm in the nulliparous adult women . In the 
anatomical position, it has a slight angulation downward and backward. The 
cervix is divided into three parts- Endocervix, Ectocervix, and 
Transformation zone. 
1. The Endocervix is the portion of cervix which extends from the 
internal os to the ectocervix and  it has the endocervical canal. The 
mucus secreting columnar epithelium that lines the endocervical canal  
is thrown into folds. The mucus secreting epithelium form folds that 
often projects into the underlying stroma forming complex glands or 
crypts 
2. The Ectocervix is the portion of cervix which extends  from the  
squamo - columnar junction to the vaginal fornices. This portion of 
cervix is lined by non keratinising stratified squamous epithelium and 
is hormone sensitive. The portion of cervix in the vagina is called as 
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exocervix. It is limited by the anterior and posterior vaginal fornices. 
It has a convex elliptical surface. The exocervix is divided into 
anterior and posterior lips. The anterior lip is shorter than posterior lip. 
The external os is present in the center of the exocervix.  
3. The Squamocolumnar Junction (SCJ)  denotes the region where the 
squamous epithelium of  ectocervix and columnar epithelium of the 
endocervix  meet. This SCJ varies in its position throughout life as a 
result of metaplastic changes that takes place in the columnar 
epithelium of the cervix. The SCJ is usually present at the external os, 
before the puberty. After child birth, the SCJ moves to the ectocervix. 
After the menopause the SCJ  moves back to the endocervical canal. 
Histology: 
The ectocervix is lined by squamous epithelium and endocervix is 
lined by columnar epithelium. Stroma of the cervix comprised of  fibrous, 
muscular, and elastic tissue. Among the stromal connective tissue, fibrous 
tissue constitutes the major portion. About 15% of the stroma is comprised 
of smooth muscle. Smooth  muscle is present mainly in the endocervix and is 
absent in ectocervix. Smooth muscle constitutes about 50-60% of the 
connective tissue at the isthmus, where it is concentrically arranged to form a 
sphincter. 
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ECTOCERVIX: 
Histology: 
The ectocervix is lined by  mature non keratinized squamous 
epithelium. This squamous epithelium in normal conditions , do not have 
rete ridges. Squamous epithelium of ectocervix has three distinct zones. 
They are as follows:  
1. Basal/parabasal or germinal cell layer, which is responsible for 
continuous epithelial renewal 
2. Midzone or stratum spinosum, the dominant portion of the epithelium 
3. Superficial zone, containing the most mature cell population  
GERMINAL LAYER: 
The germinal layer consists of  two cell types. They are basal cells and 
parabasal cells. 
BASAL CELLS: 
  The  basal cells are present just above the basal lamina. Basal cells are   
about 10 mm in diameter, having minimal cytoplasm and oval nuclei 
.Nucleus  of basal cells are arranged perpendicularly to the basal lamina.  
PARABASAL CELLS: 
Parabasal cells, compared to basal cells, are larger. Parabasal cells are 
present above the basal layer and it is 1-2 cells thick. The important function 
of both basal and parabasal cells are the regeneration of the epithelium. 
Therefore the receptor for growth factor of the epidermis are present in the 
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basal and parabasal cells. The growth factor receptors are HER-2/neu, 
estrogen receptor and progesterone receptors
(9,10)
. As the cells differentiate 
into intermediate squamous cells, the growth factor receptors are reduced in 
number. Basal cells, also have the stem cell function. Parabasal cells are the 
cells that actively takes part in the replication. As the parabasal cells are 
undergoing active replication, there is increased mitosis in this layer. Not 
only the mitotic figures , but also other proliferative markers like Ki- 67 
antigen, and other cyclins are found in parabasal cells.  
MIDZONE: 
Above the germinal layer, is the midzone. The midzone  composed  of  
cells that undergoes maturation . They differ from basal cells in having 
increased cytoplasm and the size of the nucleus remains unchanged till the 
superficial layer. These cells when exfoliated , are termed as intermediate 
cells. Intermediate cells does not undergo mitotic division. The cytoplasm of 
intermediate cells is clear and vacuolated. This vacuolation is due to the 
presence of glycogen, which is per iodic acid Schiff -positive, and  diastase-
labile.             
SUPERFICIAL ZONE: 
This zone is present in the superficial layer of the cervical epithelium. 
It is composed of superficial cells which are flattened and have abundant, 
pink,eosinophilic cytoplasm with nuclei being small and pyknotic. The 
stroma of  ectocervix composed of  fibrous connective  tissue, and there is no 
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glands in this region.  Stroma occasionally extends into the epithelium to 
produce stromal papillae. 
ENDOCERVIX 
Histology : 
The endocervix is lined by single layer of tall columnar , mucin 
secreting epithelium. The endocervical stroma consists of endocervical 
glands, which are formed by complex infolding of the lining mucin secreting 
epithelium.  The  glands of the endocervix belong to compound, tubular 
racemose, type of  glands. The lining epithelial cells are tall, columnar and 
are uniformly arranged. These cells have their nuclei being placed basally 
and have fine, granular cytoplasm filled with mucin secretions. These lining 
cells are called picket cells because of their appearance resembling a picket 
fence. There is another kind of ciliated cells, which are non secretory in 
nature, are present in the endocervix. As these cells are ciliated, they help in 
distribution and mobilization of the endocervical mucus.
(11)  
The other types 
of cells that are seen in endocervical epithelium, that can be demonstrated by 
histochemical stains, are argyrophil, neuroendocrine and argentaffin cells.
(12)  
Serotonin is present in the argentaffin positive cells.  
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TRANSFORMATION ZONE:  
The area where the stratified squamous epithelium and glandular, 
mucin secreting columnar epithelium meet is known as squamo-columnar 
junction of the cervix   
 
Fig : 1                                 Fig : 2                               Fig : 3 
Fig : 1 -  original squamocolumnar junction 
Fig : 2 – endocervical erosion with original squamocolumnar junction 
Fig : 3 – transformation zone with functional squamocolumnar junction 
  Actually, the adult cervix has two different squamocolumnar 
junctions. First one is the original squamo-columnar junction which is 
present since birth. Actually  it is the place where native ectocervical 
stratified  squamous epithelium  meets the endocervical columnar 
epithelium. The second SCJ which is formed later in life ,either during 
menarche or during pregnancy. During this period, the cervix undergoes 
alterations in shape and size. Due to these changes, the columnar epithelium 
of the endocervix moves outward towards the ectocervix. This phenomenon 
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is referred to as eversion of endocervix. Normally the  mucosa of the 
endocervix appears red and velvety,  when compared to the mucosa of 
ectocervix which is pink and translucent.  Due to the eversion of endocervix, 
during puberty or pregnancy, columnar epithelium in this area undergoes 
remodeling, and is replaced by metaplastic squamous epithelium .As this 
occurs, the histological squamocolumnar junction moves toward the external 
os. This newly formed squamocolumnar junction is called the physiologic, 
functional, or new squamocolumnar junction. The area that lies between the 
original squamocolumnar  junction and the physiologic squamocolumnar 
junction is known as the transformation zone. The transformation zone 
comprises of metaplastic squamous epithelium. 
 
 
 
 
 
 
 
 
Fig :4 Histology of transformation zone 
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Nearly all the neoplastic lesions of the cervix arise from this newly 
formed physiologic squamo-columnar junction and  cervical cancer 
precursors occurs within this  transformation zone. 
INVASIVE CARCINOMA 
The invasive carcinoma of cervix is generally categorized into three 
main groups by World Health Organisation as follows: 
1. Squamous cell carcinoma,  
2. Adenocarcinoma, and  
3. Other epithelial tumors. 
Among all the tumors, the most common histologic type of tumor is 
Squamous cell carcinoma which accounts for about 70–80% of invasive 
carcinomas. The next common tumor to occur will be Adenocarcinoma and 
Adenosquamous carcinoma accounting 10–15% of all cases. Squamous cell 
carcinomas  mostly arise from precancerous lesion and also arise from 
human papilloma viral infection, especially those which are persistent in 
nature 
(13)
. Regarding  precancerous lesion, nearly 10% to 20% of  CIN III 
lesions if left untreated, eventually progress to frank malignancy. The 
transformation of CIN III to carcinoma may take many years and this varies 
from 3yrs to more than 20 years.
(14)
 
The majority of squamous cell carcinomas occur in women who are 
between ages 40 and 55, with approximately 10% less than 30 years of age. 
Mean age for patients is approximately 51 yrs. At least 50% are stage I when 
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diagnosed. Of stage I tumors, 10% to 15% will be less than 5 mm in depth 
(stage IA). Survival is close to 100% for stage IA and diminishes with 
invasion beyond 5 mm and extension beyond the cervix (stage IIA)  .  The 
stage of cancer at the time of diagnosis is important as it is closely related to 
lymphnode metastases and thus determines the survival of the patient 
.Cervical carcinoma mainly spreads through superficial and deep lymphatics  
which finally drains into iliac, common iliac, obturator , hypogastric and 
sacral lymph nodes, as well as lymph nodes in the posterior bladder wall. 
The survival year of 5 yrs is reduced to 30% to 35% for stage III neoplasms. 
RISK FACTORS: 
The risk factors for cervical carcinoma includes viral causes and non 
viral causes.Viral cause includes HUMAN PAPILLOMA VIRUS 
infection.Other non viral causes are as follows: 
 Multiple sexual partner 
 Age 
 High Parity 
 Immune Status 
 Certain HLA subtypes 
 Use of oral contraceptives 
 Use of nicotine 
 Chlamydia infection 
 Lesbainism 
Human Papilloma viruses 
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HPV infection is the etiologic agent for the great majority of cervical 
epithelial neoplasms.  Several studies including clinical and molecular 
studies have shown that HPV infection is strongly associated with cervical 
cancer and it directly influences the pathogenesis of cervical cancer. Over 
the past several years,it was observed  that:  
 HPV infection is ubiquitous in the young sexually active population,  
 Frequency of infection peaks in the early reproductive years 
 Usually the HPV infections are  transient in nature ,which clears off  
and again it reappears,  producing no cytological abnormalities.  
 if the infection  occurs persistently and it is produced by the HPV of 
same subtype, then there is high risk for the development of cervical 
cancer
(15)
 
Cancer-associated (“high-risk”) HPV types impose a broad gradient of 
risk, with HPV-16 conferring the greatest risk. Low-risk HPV types may 
confer risk as surrogate markers of “at-risk behavior.” More than 100 human 
papilloma  viruses have  been discovered .Among the 100 types, nearly forty 
HPV types are found to infect genital tract. These HPV that are known to 
produce genital infections have been classified into low risk, high risk and 
intermediate risk types .The high risk has HPV has strong tendency to 
produce cervical carcinoma.
(16)
  The HPV not only been associated with 
carcinoma but also produce preinvasive lesions. 
TYPES OF HPV : 
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Kahn and associates followed women with mild cytologic atypia and 
correlated the outcome of CIN-3 at 10 years with HPV type. The relatively 
strong association between HPVs 16 and 18 and CIN-3 (15%to 18%) versus 
all other high-risk HPV types (3%) and low-risk HPV types (<1%) show 
HPV-16 as the prototypic high-risk type.
(16)
. A more recent study by Castle 
et al. showed that two high-risk or oncogenic HPV tests within 
approximately 1 year conferred a risk of CIN-2+ biopsy at 3 years of 17%, 
which increased to 41% for HPV-16
(17)
 .  
The relationships between HPVs and cervical neoplasia vary both for 
lesion grade and cell type. 
 HPVs 6 and 11- are not associated with cervical carcinomas or high-
grade squamous intraepithelial lesions. HPV-16: Nearly half of the 
HSIL  cases  have  infection with HPV-16 and this  infection is also 
strongly associated with squamous cell  carcinoma of the  cervix. HPV 
-16 is called  the prototypic cancer causing virus  
 HPV-56 – very few cases only (about 1 in 50) have this infection.    

 HPV-18 – This  type of  HPV accounts for about 15% of squamous  
cell carcinoma of cervix.HPV 18 is also associated with  
adenocarcinoma   and  adenocarcinomain situ. HPV-18 is strongly   
associated with  small cell neuroendocrine carcinoma. 
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A newly discovered HPV types –found to have uncertain or 
controversial association with cancer. They have been suggested to have 
presumably a low risk of cancer
(18)
. 
 
Prevalence rates of high-risk HPVs vary somewhat among different 
regions of the world and different countries.  HPVs 16 and 18 are the 
dominant HPVs detected, ranging from 64% to 77% across different 
continents
(19)
.The  higher levels of viral DNA (viral load) correlate with risk 
of SIL
(20)
 However, viral load will not discriminate low- from high-grade 
SIL because viral production is often higher in low-grade lesions. For this 
reason, viral load is not used as a predictor for HSIL. 
Persistent infection by the same HPV type is strongly associated with 
risk of cervical neoplasia. Usually many types of  HPV  produce infection 
that are transient in nature.  In  various studies that dealt with several  types 
of  human papilloma virus, it had been found that persistent infections which 
were produced by same type of  papilloma virus has highest risk of 
progression to cervical carcinoma
(21)
.   In the studies done retrospectively on 
cervical cancer ,also shows high percentage of  cases being infected with 
human papilloma virus.
(22)
  
Elfgren et al. found that 92% of HPV-positive cases turned negative 
for infection over a 5-year period. But  with HPV type 16 specifically, 
persistence of infection is highly related to the CIN and squamous cell 
carcinoma.  
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Conversely, Clavel et al. showed that approximately one third of high 
risk HPV  positive women developed HSIL and two thirds of persistently 
high-risk HPV- positive women developed  LSIL
(23)
.Hopman et al. and 
Nobbenhuis et al.in their studies found that persistent infections with high 
risk HPV subtypes, had developed abnormalities in cervical smear, in more 
than 90% of cases .
(24)
 
HPV intratypic variants exist and appear susceptible to the viral-like 
particle vaccines. Prior studies of different intratypic variants of HPV-16 
showed that all were susceptible to the HPV-16 vaccine.
(25)
 
Nonviral Factors: 
Various host and behavioral factors are said to produce cervical cancer 
or HPV infection. They are as follows: 
HLA type: 
HLA that belongs to class II haplotypes (linked class II alleles) are 
generally related to cervical intraepithelial neoplasia and invasive carcinoma. 
Among this certain class II alleles are related to LSIL, HSIL, and full blown 
malignancy , but certain other type II alleles  are protective in nature.
(26)
 Still 
others have been associated with infection alone or certain HLA types are 
associated with cancers produced by certain HPV types, such as type 16. The 
studies observed that specific HLA class II haplotypes may influence HPV 
antigen presentation and the immune response to HPV infection, in turn 
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influencing the risk of developing invasive cervical carcinoma. The  precise 
mechanisms underlying these associations is still under study. 
2.Age: 
Young, sexually active women are at greatest risk for HPV infection 
and  preinvasive cervical neoplasia. This risk gets reduced significantly with 
increasing age, which is associated with increasing risk of cancer . There is a 
reduced risk  with the attainment of menopause. Thus the HPV infection risk 
is increased in young age and is reduced as the age increases. The 
progressive drop in risk with increasing age has been attributed to an 
effective immune response to the virus that follows the onset of sexual 
activity and exposure to HPVs. Protection is long lasting, given the low rates 
of  HPV positivity in middle-age women. 
 3.Immune status: 
Immunodeficient  status  in certain conditions like HIV infection, post  
transplantation, immunosuppresed individuals have increased risk of 
developing cervical carcinoma. In post transplant therapy, there is deficient 
cell mediated immunity and therefore increased risk of cervical cancer. HIV-
infected individuals are prone to HPV infection, persistent HPV  infection, 
and a higher risk of  precursor lesions. The prognosis of cervical cancer in 
HIV infection appears to be worse in patients with severe 
immunodeficiency. The risk of cervical neoplasia or HPV infection in 
immunosuppressed individuals is well established. The patients with 
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transplants have higher risk of  HPV positivity.
(27)
 Cancer rates are higher in 
this population, and in general anogenital cancers occur at a younger age. 
The rate of the virus infection in the  immunosuppressed patients were found 
to be increased 9 folds when compared to the  general population and  much 
more higher nearly about seventeen times, in matched immunocompetent 
patients
(28)
 .About one third of  HPV infected individuals and nearly 50% of 
cancer patients have involvement of multiple sites in the lower genital tract. 
4.The male partners: 
The role of the male partner can be summarized as follows: It has been 
proposed that if the male partners have multiple sexual partners, it influences 
the risk of cancer development, even though it is of lesser degree. There  is 
little evidence that the male partner re-infects the woman, at least with the 
same HPV type. Krebs and Helmkamp showed that treating the male partner 
did not influence risk of recurrent genital warts.
(29)
 The implication of this 
study is that partners are not reinfected by the same virus, consistent with a 
functioning immune system. Kjaer et al. found that repeated sexual contacts 
of the male partner with other women did not increase risk independently, 
whereas a history of genital warts and absence of condom use did increase 
the risk. Condoms protect against HPV infections and significantly reduce 
the risk of cervical HPV infection. Circumcision reduces the risk of infection 
in the male partner and his female contacts, producing a relative risk of 0.65 
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in the male. Other infections, such as syphilis and HIV, are also significantly 
reduced in circumcised men
(30).
 
5.Oral contraceptives.  
 The use of oral contraceptives has shown to have increased risk for 
the development of carcinoma cervix.There is a strong theoretic basis for 
hormones influencing epithelial growth and susceptibility to neoplasia in the 
cervical ransformation zone
(31)
. Oral contraceptive use and plasma levels of 
hormone have been associated with cervical neoplasia
(32)
; however, 
Kjellberg et al. and Coker et al. noted an association between OCPs and 
cervical neoplasia but the association disappeared when HPV was taken into 
account
(33)
. There is a strong association between  hormonal replacement and 
cervical adenocarcinoma. A recent large meta-analysis postulated a relative 
risk of 1.90 with use of  oral contraceptive pills greater than 5 years and a 
decline in risk with cessation of  use.
(34)
 
6.Smoking.  
Smoking increases the risk of cervical neoplasia, but the mechanism is 
unclear. Kjellberg et al. noted a strong (independent of HPV) association 
between smoking and cervical neoplasia
(35)  .
The theoretic basis is 
presumably the presence of DNA adducts in the cervical mucus, exposing 
the transformation zone mucosa to carcinogens. Genetic polymorphisms that 
theoretically do not reduce adduct formation have also been implicated. 
Lacey et al. showed a positive relationship to squamous but not 
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adenocarcinoma.
(36)
 Deacon et al. also showed a dose- response 
relationship
(37)
 A retrospective study in a Nordic population showed an odds 
ratio of 2.7 for women with nicotine in their serum after controlling for the 
presence of HPV-16/18 antibodies.
(38)
. 
7.Chlamydia infection.  
The association between chlamydia infection and cervical neoplasia is 
controversial. Anttila et al. found that evidence of infection with chlamydia 
serotype G conferred a significant risk of cervical cancer
(39)
. Several studies 
have shown a relationship between genital infections and HPV or HSIL  
8.Women who have sex with women.  
Risk of cervical neoplasia is increased in women who are lesbians. 
Studies have shown high rates of sexually transmitted infections in women 
who have sex predominantly with other women,but the occurrence of  
genital condylomata were low. However, the risk of developing HSIL was 
not determined. Two reports have shown that CIN-2 may occur in lesbian
(40)
 
In summary, a multitude of factors, viral and host related factors, influences 
risk of cervical  neoplasia before, during, and following exposure and lesion 
progression. . 
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TABLE no:1 Risk factors for HPV infection and cervical neoplasia:  
(35,26,33,28) 
FACTORS 
OUTCOME 
VARIABLE 
POSITIVE/ 
NEGATIVE 
Young age at coitus HPV + HSIL Positive 
Sex partner>2 HPV INFECTION Positive 
Recent sexual activity HPV INFECTION Positive 
Male promiscuity CARCINOMA Positive 
Parity (>7) CARCINOMA Positive 
Increasing age HPV Negative 
Cervicitis  HSIL Positive 
Genital infections HPV Positive  
Chlamydia infections ( 
type G) 
SQUAMOUS CELL 
CARCINOMA 
Positive 
 
Barrier contraception HSIL/ CARCINOMA Negative  
Smoking  
 
CIN-2/3 or CIN- 
3/carcinoma 
Positive  
 
Oral contrceptives or 
unopposed estrogens 
ADENOCARCINOMA 
 
Positive  
 
Oral contraceptives CARCINOMA Positive  
High risk HPV CARCINOMA Positive  
Persistent infection 
with high risk HPVS 
HSIL, CARCINOMA 
 
Positive  
High viral load(HPV) HSIL Positive 
HLA -B 07 &            
HLA- DQB1-302 
HSIL/ CARCINOMA 
Positive  
 
Transplantation   CERVICAL Positive  
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 CARCINOMA  
 
HIV INFECTIONS 
Index of HPV Positive (2 fold) 
 Persistent HPV Positive (6 fold) 
 SIL Positive (4 fold) 
 Persistent of  SIL Positive (4 fold) 
 HSIL/ CARCINOMA Variable (0-15 fold) 
 
HISTOPATHOLOGY: 
SQUAMOUS CELL CARCINOMA: 
Invasive  squamous cell carcinoma  have variying gross 
presentations.They may present either as focally indurated lesion, or 
ulceration or as an elevated lesion, that easily bleeds. Most of the  early 
carcinomas of cervix are present within the transformation zone.The 
advanced carcinomas of cervix mostly present either as a exophytic mass or 
an endophytic growth. The exophytic growth usually have a papillary or 
polypoid mass. Endophytic growth of carcinoma cervix  grossly appears as 
ulceration or as  nodules. Generally these growth occurs in the endocervical 
canal and often they invade into the underlying cervical stroma. 
Microscopy: 
       On histopathological examination, squamous cell carcinoma is 
characterized by invasion of neoplastic squamous cells into the stroma , 
forming anastomosing cords in the stroma. The margins of the infiltrating 
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cords of malignant squamous cells, are irregular and have ragged edges.The  
invasion of the tumor into the stroma occurs either as an individual tumor 
cells or as a large mass that totally replaces the stroma.  
The centre of the infiltrating  malignant squamous cells undergoes 
necrosis  or sometimes they undergo intense keratinisation. The individual 
tumor cells are  large, polygonal in shape or sometimes oval with acidophilic 
cytoplasm. Usually the cell membranes of the malignant squamous cells are 
prominent and the intracellular bridges may or may not be present. The 
tumor cells exhibit relatively uniform nuclei, with occasionally showing 
pleomorphism. The  nuclear chromatin being coarse and clumped. Generally 
the mitotic figures are seen, and often abnormal forms are also seen. 
HISTOLOGICAL TYPES: 
The squamous cell carcinomas of the cervix were classified depending 
upon the type of cell that is predominantly seen. The recent classification by 
WHO(Annexure -2) of  cancer cervix classifies small cell carcinoma with 
neuroendocrine features as a separate entity. The invasive squamous cell 
carcinomas is broadly grouped under two  major groups,namely keratinizing 
and nonkeratinizing
(41)
. 
KERATINISING  SQUAMOUS CELL CARCINOMA:   
The squamous cell carcinoma of keratinizing type is a lesion 
composed of  malignant squamous cells arranged in cords or nests that show 
variation in shape and size . The characteristic feature of this type of 
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carcinomas is the  keratinisation of the tumor cells. The evidence of 
keratinisation is appreciated by the presence of keratin pearls within the 
epithelium, or the presence of  kerato hyaline granules or the individual 
keratinized cells and nests of squamous cells  with central keratinisation. It 
has been proposed that even one keratin pearl, if present , is enough to 
categorize this tumor as a keratinizing carcinoma. The nests of squamous 
cells  are arranged in a concentric fashion and they undergo keratinization to 
form the characteristic keratin pearls. The malignant  squamous cells that 
doesnot form pearls, often show abundant acidophilic cytoplasm with their 
intercellular bridges being prominent.These changes are referred to as 
individual cell keratinisation. The tumor cells have enlarged nuclei and the 
mitosis is not high. These tumors are usually termed as well differentiated  
carcinoma and they have a pushing border of invasion.  
NON KERATINISING SQUAMOUS CELL CARCINOMA: 
As the name implies, these tumor does not have characteristic keratin 
pearls. This tumor histologically shows the nests of malignant squamous 
cells that undergoes individual cell keratinisation. Individual tumor cells are 
large with indistinct cell margins and exhibit greater degree of nuclear 
pleomorphism , with round to oval nuclei,having coarse,clumped chromatin. 
They often have numerous mitotic figures.  
These tumors have an infiltrative border and often associated with 
inflammation. These tumors are referred to as moderately differentiated . 
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MICROSCOPIC GRADING: 
Recently squamous cell carcinomas are graded histologically as follows: 
1. Grade I-Well differentiated 
2. Grade II -Moderately differentiated  
3. Grade III - Poorly differentiated  
In general, the most commonly occurring tumor belongs to grade II, 
that is moderately differentiated  squamous cell carcinoma. Next frequent 
tumor would be  grade III( poorly differentiated ), followed by grade I (well 
differentiated)  
Well-differentiated squamous cell carcinoma: 
This carcinoma is characterized by the presence of  keratin pearls, 
individual cell keratinisation and prominent intercellular bridges.   
The  tightly packed cells have irregular , hyperchromatic nuclei. 
Mitosis is seen at the advancing  margin of the tumor.There is often 
inflammatory reaction in the stroma , with occasional giant cells of foreign 
body type. 
Moderately differentiated squamous cell carcinoma:  
The  grade II tumor cells  are large, with irregular nuclei showing 
moderate pleomorphism with decreased amount of cytoplasm. They have 
indistinct cell margin and  intercellular bridge. Keratin pearls are absent. 
Tumor cells show individual cell keratinization and the increased mitosis. 
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Poorly differentiated squamous cell carcinomas :                           
The tumor cells show severe pleomorphism with scanty cytoplasm and 
oval, hyperchromatic nuclei. Occasionally there are giant cells with bizarre 
nuclei can be seen. There is complete absence of keratinisation. Rarely the 
cells may appear spindle shaped.  They have increased mitotic rate and areas 
of necrosis  
VARIANTS OF SQUAMOUS CELL CARCINOMA: 
Verrucous carcinoma 
It is a rare variant , which is a highly differentiated type of squamous 
cell carcinoma .On gross it appears to be polypoid in nature, and have an 
extremely well-differentiated cytologic appearance, and a capacity for local 
invasion but not for metastatic spread. Some cases have been found to 
extend into the endometrial cavity.
[42]
It should be distinguished from 
condyloma acuminatum and  squamous cell carcinoma with a prominent 
papillary pattern of growth . 
Spindle cell carcinoma 
(sarcomatoid carcinoma; squamous cell carcinoma with sarcoma-like 
stroma; carcinosarcoma)  
This carcinoma is morphologically analogous to the homonymous 
tumor in the upper aerodigestive tract.
[43]
 It may contain osteoclast like giant 
cells,
[411]
 and there is often evidence of HPV infection.
(44)
 The epithelial 
component of this tumor, when present, this is usually of squamous type.   
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Basaloid (squamous cell) carcinoma 
Basaloid carcinoma is characterized by prominent peripheral 
palisading, an infiltrative growth pattern, and minimal stromal reaction
[45]
.  
This tumor is aggressive and the differential diagnosis for this are the 
adenoid cystic carcinomas and adenoid basal carcinomas.  
Lymphoepithelioma-like carcinoma  
This carcinoma resembles its counterpart in the upper respiratory tract 
by virtue of the large size of the tumor cells, vesicular nuclei with prominent 
nucleoli, syncytial appearance, and heavy lymphocytic infiltration.
[46]
. Some 
cases have been found to secrete beta HCG 
Transitional cell ( urothelial ) carcinoma:  
This lesion having an appearance similar to the tumor located in the 
bladder or ovary . It needs to be distinguished from inverted  transistional 
cell papilloma and papillary squamous cell carcinoma. 
MICRO INVASIVE SQUAMOUS CELL CARCINOMA: 
This is also called as early invasive carcinoma of cervix. This tumor 
lies in between the spectrum of CIN and well established invasive 
carcinoma. According to FIGO staging, it is placed under stage IA. This is 
defined as tumor less than or  equal to 3mm in depth and 7mmin length. 
There is no capillary or lymphatic invasion .Diagnosis of MICA can be made 
only by histopathological examination.  
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The  criteria for diagnosis are desmoplastic reaction of the stroma, 
well matured squamous cells, and loss of polarity, necrosis in the lumen. 
Common age of presentation, falls between 35 – 46 yrs. It constitutes about 
20% of all cancer of cervix. High grade SIL with endocervical crypt 
involvement is associated with  MICA. 
CERVICAL INTRAEPITHELIAL NEOPLASIA: 
The term cervical intraepithelial neoplasia includes all  squamous cell 
alterations that is produced in and around the transformation zone  and 
usually associated with human papilloma virus infection. This is considered 
to be the precancerous lesion of the cervix. They have been  classified as 
mild , moderate and severe dysplasia according to oldest classification. 
According to WHO ,it has been  classified as CIN I, CIN II, CIN III. 
Bethesda system classifies the lesions based on the cytology as LSIL, HSIL. 
The characteristic feature of CIN was that the  cellular atypia  did not 
involve the entire epithelium and might involve one third or two third of the 
cervical epithetlium. Other distinguishing feature was that it did not have 
invasion of stroma neither there was disruption of basement membrane. 
Actually mild dysplasia corresponds to CIN I, moderate dysplasia 
corresponds to CIN II, and CINIII includes both severe dysplasia and 
carcinoma in situ. 
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TABLE no : 2 Terminologies for cervical cancer precursors: 
Older classification  
WHO 
classification 
 
Bethesda 
system 
terminology 
Mild dysplasia  CIN I  LSIL 
Moderate dysplasia  CIN II  HSIL 
Severe dysplasia/carcinoma in situ  CIN III  HSIL 
 
CIN- I: 
In this category, nuclear atypia which is usually mild and  nuclear 
abnormalities are  present in the lower one third of cervical epithelium. 
Mitosis may not be prominent. Nuclear atypia with perinuclear clearing is 
called koilocytic atypia. The cells in the  upper two thirds of the epithelium, 
are usually matured. 
CIN – II:         
Here nuclear abnormalities and nuclear atypia is seen in lower two 
third of the cervical epithelium. Mitotic figures are limited to the basal two 
third layers of cervical epithelium and occasionally have abnormal mitotic 
figures. 
CIN – III: 
In this type , there is marked nuclear abnormalities and atypia is seen 
through entire thickness of the cervical epithelium with absence of 
33 
 
maturation throughout. As it is high grade, it has increased number of mitotic 
figures, as well as abnormal forms.  
Human papilloma viruses are strongly related to cervical 
intraepithelial neoplasia, especially with high risk strain of HPV. HPV 
infection interfere with and alters  the cell cycle. The cell cycle biomarkers 
are helpful in distinguishing CIN from other atypia. Ki- 67  is a cell 
proliferation marker,which is normally seen in the suprabasal cells. Another 
recently identified marker of CIN is  P 16 , a cyclin dependent kinase 
inhibitor. 
Normal cervix                  LSIL              HSIL                           invasive carcinoma 
 
Fig : 5 Evolution of CIN(SIL) and invasive carcinoma from normal cervix 
epithelium 
As CIN is closely related to HPV infections, HPV linked cytologic 
abnormalities like koilocytic atypia, multinucleated cells, and dyskeratosis 
are seen. The cytologic changes like enlargement of cells, with increased 
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size of the nucleus, often nucleus showing binucleation associated with 
irregular nuclear membrane and  hyperchromasia. 
Hyperplasia of reserve cell with atypia squamous metaplasia with 
atypia are regarded as CIN variants. 
Cytopathology: 
CIN is graded cytologically depending on the nucleus morphology. 
CIN I : Epithelial  cells show little enlargement of nucleus, which 
occupies about one third of the cell, mild degree of anisokaryosis and 
hyperchromasia. Nuclear chromatin is distributed evenly and have fine 
granules.  
CIN II : There is marked variation in shape and size of the cell, as well 
as the nucleus. The nucleus occupies about half of the cell, and the 
chromatin is irregular and have moderate hyperchromasia. 
CIN III: The nucleus occupies more than two third of the cell with 
hyperchromatic nucleus. The chromatin is irregular and have coarse 
granules. 
Carcinoma in situ :  The tumor cells are arranged in syncytial 
aggregates or as a single cells , characterized by nuclear overlapping and cell 
margins are indistinct, with scant cytoplasm , oval to round nucleus. 
ADENOCARCINOMA: 
Primary adenocarcinomas make up 5–15% of all carcinomas of the 
cervix. Incidence is on the rise in the general population, particularly in 
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young women.
[47]
 An association has been found between the long-term use 
of oral contraceptives and the development of endocervical neoplasia in 
young patients,
[48]
  The tumor shows no distinguishing gross features.  
Microscopically, the most common pattern is that of a well-
differentiated glandular pattern with mucin secretion, some of which can 
leak into the stroma
[49]
 However, the degree of differentiation varies, and 
poorly differentiated forms exist. In addition to the mucin-secreting 
appearance, which recapitulates the histology of the normal endocervix, 
cervical carcinomas can have an endometrioid or a serous (papillary) 
appearance. 
Endometrioid adenocarcinoma 
It looks similar to its counterpart in endometrium. Endocervical type 
of endometroid adenocarcinoma is usually associated with HPV infection 
and adenocarcinoma in situ. This cancer occurs in younger age group 
patients.  The factors that favours the endocervical origin are: the majority of 
the tumor occurs in the endocervical  region, presence of cervical mass, its 
association with HPV infection, and adenocarcinoma in situ, younger age. 
Serous (papillary) carcinoma:  
The Primary serous adenocarcinoma of the cervix is extremely 
uncommon.  Usually it  has  bimodal pattern of presentation that is below 45 
yrs and above 65 yrs. Grossly it appears as  exophytic or polypoid mass. 
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These tumors are histologically similar to papillary serous adenocarcinoma  
of any FGT tumor.  
They have complex branching papillae, with cellular tufting , 
micropapillae and slit like spaces are seen. Numerous mitotic figures are 
seen and are commonly associated with villoglandular  adenocarcinoma. 
Adenoma malignum 
Synonym: minimal deviation adenocarcinoma 
This tumor type  is a rare entity, which is well differentiated mucinous 
tumor. Minimal deviation adenocarcinoma is usually associated with 
mucinous ovarian carcinoma and sometimes with Peutz- jeghers 
syndrome.
(50)
  
Histologically, they composed of infiltrating , irregular glands, and 
sometimes extend to the outer third of cervix
(51)
. The neoplastic glands are 
lined by mucinous epithelial cells with  pale eosinophilic cytoplasm and 
small nucleus located basally with few cells showing prominent nucleoli , 
with focal desmoplastic reaction of the stroma.The neoplastic glands secrete 
neutral mucin. They are rarely associated with HPV infections. 
Villoglandular Adenocarcinoma: 
This is an uncommon variant of adenocarcinoma. Tumors often have  
an exophytic polypoid or papillary growth. The  characteristic feature of this 
tumor is the  surface papillary component which has  finger-like papillae in 
the background of fibrous spindled stroma. The papillae is lined by stratified 
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columnar epithelium with nucleus showing mild nuclear atypia. This type of 
carcinoma is  usually associated with HPV infection of  high-risk strains  
namely types 16 and 18 and also is accompanied by adjacent 
adenocarcinoma in situ. 
Adenosquamous (mixed) carcinoma  
The mixed carcinoma  has elements of both squamous and glandular 
components. This carcinoma arise from sub columnar reserve cell
(52)
. It is 
related to pregnancy and it resembles mucoepidermoid carcinoma of salivary 
gland and is said to have poor prognosis.  
Glassy cell carcinoma: 
It is a special type of adenosquamous carcinoma as this cancer 
exhibits feature of both squamous and glandular components. This tumor 
occur in a younger age group than cervical adenocarcinoma. They present  as 
a large, bulky, fungating mass grossly . Histologically the tumor consists of  
tumor cells arranged in diffuse sheets and nests of large cells, with abundant 
eosinophilic finely granular cytoplasm giving a ground-glass 
appearance,with enlarged nucleus and prominent nucleoli with prominent 
cell margin. The stroma is infiltrated by chronic inflammatory cell infiltrate, 
which includes eosinophils and plasma cells. There are numerous mitosis 
seen. Generally, it has worse outcome.
(53)
  
 
 
38 
 
Mucinous carcinoma: 
Mucinous carcinoma of the endocervix remains an ill-defined concept. 
Its immunophenotype  can be of gastric or intestinal type, including 
immunoreactivity for  CK7, p16, and a new  marker known as HIK1083.
[54]
 
This tumor type is said to run a more aggressive clinical course than the 
usual type of endocervical adenocarcinoma.
[55]
 
Adenoid cystic carcinoma: 
This variant is rare in cervix, commonly occurs in postmenopausal age 
group patients
(56)
. Grossly it is friable polypoid or ulcerated mass . It has 
worse prognosis as it has high rate of recurrence focally and also distant 
metastasis. 
Histologically, cervical adenoid cystic carcinoma has similar features 
as that of its counterpart in salivary gland tumor . Histologic hallmark of this 
tumor is its cribriform pattern with an empty space surrounded by 
pallisading nuclei. The empty space sometimes show eosinophilic secretions 
that is hyaline or mucinous in nature. This tumor has numerous mitotic 
figures, and extensive necrosis. Individual tumor cells show pleomorphism 
and the stroma exihibit dense desmoplastic reaction. Immunohistochemically  
they are positive for S-100 and HHF35. 
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Adenoid basal carcinoma (Adenoid basal epithelioma) tumor; 
epithelioma) :  
It is a low grade lesion. It has similarities with adenoid cystic 
carcinoma. The prognosis is excellent and generally do not have metastasis 
or recurrences. They doesnot produce mass lesion
(57)
. In some instances, they 
are associated with adenosquamous carcinoma, adenoid cystic carcinoma or 
cacinosarcoma. They are related to HPV infection of high risk strain and 
with HSIL. They present histologically as discrete rounded nests and islands 
of atypical squamous cells with prominent pallisading of nucleus or as nests 
of basaloid cells or basaloid cells admixed with acinar or glandular 
structures. 
Clear cell carcinoma  
Synonym:   formerly called as Mesonephric carcinoma              
This tumor has bimodal age distribution. They may occur sporadically 
or due to the use of diethylstilbesterol in utero. Microscopically, the tumor 
composed of neoplastic glands that  are lined by large cells with  abundant 
clear cytoplasm, and hyperchromatic nuclei. They also may be arranged in 
tubulo-cystic pattern , or papillary pattern  or in solid pattern. Hobnail cells 
can be frequently made out. This cancer arises from mullerian ducts. This 
variant has good prognosis. 
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Mesonephric (adeno)carcinoma 
These carcinoma arise from mesonephric remnants. These tumors 
grossly present as exophytic mass or polypoid mass or the enlargement of 
cervix diffusely, which is referred to as the barrel cervix. This cancer 
involves the entire thickness of the cervical epithelium and has an infiltrating 
margin, and occasionally it may erode the cervical mucosa.  Mesonephric 
hyperplasia is usually present. They present with various different pattern 
like ductal, tubular pattern.  
Other patterns are reteform , solid and sex cord pattern, rarely show 
spindled
(58)
 pattern also. The spindled pattern , histologically looks similar to 
endometrial stromal sarcoma and non specific spindle cell stromal sarcoma.  
Immunohistochemically they show positivity for  CK7 and calretinin 
and CD10. PAX-2 is negative. The ductal variant has to be differentiated  
from  endometroid adenocarcinoma, which has intraluminal eosinophilic 
material. The tubular variant has to be differentiated from mesonephric 
hyperplasia. This is a a very rare tumor. 
There are few rare variants of endocervical adenocarcinoma which are 
signet ring type, microcystic type, small intestinal type, and adenocarcinoma 
with hepatoid differentiation and choriocarcinomatous differentiation. 
EARLY INVASIVE ADENOCARCINOMA 
Early invasive carcinoma is difficult to differentiate from 
adenocarcinoma in situ.The main differentiating feature is the invasion of the 
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stroma, which is present in early invasive carcinoma.The invasion may be 
identified by following features: 
Glands with atypia in deeper region, single glands , small and irregular 
glands, intensive glandular budding, stroma showing desmoplastic reaction 
with inflammatory reaction, presence of back to back glands, complexely 
branched papillary architecture. Lymph node metastasis is very rare 
ADENOCARCINOMA IN SITU: 
A lesion in which normally situated glands are partly or wholly 
replaced by cytologic malignant epithelium, and the border is 
characteristically sharp. Intracytoplasmic mucin is absent in the lining 
epithelium, and looks like endometrial glandular epithelium. Occasionally, 
the lining epithelium of the glands contain intestinal goblet cells and paneth 
cells. The neoplastic glands present in the expected location of normal 
endocervical glands and donot extend beyond the deepest normal crypt. 
Commonly they have adenoid cystic carcinoma like pattern. The glands are 
lined by stratified and are arranged perpendicularly to the basal layer. The 
nucleus is oval, and hyperchromatic with mild pleomorphism and is located 
basally. Mitosis are common and are present on the luminal side. Apoptosis 
is prominent. The neoplastic epithelium may affect the surface , where it is 
often single layered , but more commonly is found in the crypts. The cell 
types, in order of frequency are endocervical, endometroid and intestinal and 
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a rare tubal variant. Although the stroma may be intensely inflamed, there is 
no desmoplastic reaction.  
Adenocarcinoma in situ is associated with CIN in at least 50% of 
cases and is immunoreactive for carcinoembryonic antigen in 80% of cases.             
NEUROENDOCRINE CARCINOMA: 
Synonym: (atypical) carcinoid tumor, argyrophil cell carcinoma, 
(extrapulmonary) small cell carcinoma, neuroendocrine carcinoma, and 
carcinoma with neuroendocrine differentiation. The age distribution of 
neuroendocrine carcinoma of the cervix and association with  HPV
(59)
 are the 
same as for squamous cell carcinoma. The carcinoid syndrome is invariably 
absent, but some cases have been seen in association with Cushing 
syndrome, and with inappropriate secretion of antidiuretic hormone (ADH). 
In contrast to squamous cell carcinoma, CIN changes in the adjacent 
epithelium are extremely rare. A possible precursor lesion in the form of 
endocrine cell hyperplasia of the cervix has been identified.The better 
differentiated tumors have an organoid arrangement, with trabecular, insular, 
glandular, and spindle patterns of growth.
 
Argyrophilic (but not argentaffin) 
granules can be demonstrated in many of the cases, particularly the better 
differentiated tumors. Amyloid may be deposited in the stroma. 
Ultrastructurally, a variable number of dense-core secretory granules are 
found in all but the most undifferentiated types. Immunohistochemically, 
positivity may be found for neuron-specific enolase, CD56,
[60]
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chromogranin, synaptophysin, 5-hydroxytryptamine (serotonin), other 
generic neuroendocrine markers,
[61]
 and a variety of peptide hormone. They 
also commonly express keratin CEA, TTF1 and p16.  The large majority of 
these cervical neoplasms are histologically and clinically aggressive.
[62]
 The 
prognosis is generally poor. 
A definite relationship exists between degree of microscopic 
differentiation and clinical behavior, the outcome being particularly worse 
for the small cell carcinomas.There is also a close relationship between 
clinical stage and prognosis.
[63]
 Both small cell and large cell neuroendocrine 
carcinomas with a polypoid shape or arising in polyps may be associated 
with a more favorable prognosis.  
HISTOPATHOLOGIC PROGNOSTIC FACTORS: 
The histopathologic prognostic factors are clinical staging, size of the 
tumor, depth of invasion , age of the patient, lymphnode metastases and 
parametrial extension. In these factors, the clinical staging of the tumor is the 
most significant one. Histological tumor types does not have significant 
effects on prognosis. 
Staging of disease: 
The clinical staging of the disease at the time of diagnosis is an 
important prognostic factor and it determines the survival of the patient 
(FIGO STAGING- ANNEXURE 3). In stage I disease, there is difference in 
survival rate between IA and IB. generally stage I has better survival rate. 
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About 95% of patients belonging to stage IA has 5-yr survival rate. This 
percentage gets reduced to about 80% to 90% in patients with stage IB and 
still gets reduced to about 75% in cases with stage II and still lower to 50% 
for stage III. Stage IV patients usually presents with local metastasis to 
adjacent kidney, bladder, urethra, at the time of diagnosis. So the survival of 
these patients is generally reduced and they die of complication due to local 
metastasis. 
Histological types: 
Poorly differentiated carcinoma and small cell carcinoma has bad 
prognosis than other types. Adenocarcinoma  has 10%  lower 5 year survival 
rates than squamous cell carcinoma.  
Size of tumor: 
Generally tumor of small size has better prognosis than larger tumor. 
The 5-yr survival rate of the tumors of size less than 3 cm were about 86%. 
Tumor of size 3-5 cm has 5 yr survival rate of about 76%. For tumors of size 
larger than 5 cm ,the 5-years survival rates were 61.5%. 
Depth of stromal invasion: 
It is the distance to which tumor had extended into the stroma. It is 
measured from the basal layer of the epithelium to the deepest point of tumor 
extension. When the depth of invasion is more, there is a high chance for the 
lymphnode metastasis and parametrial extension and recurrence of tumor.  
The stroma that is free of tumor serves as a barrier
(64)
 to the spread of tumor.   
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Lymphovascular invasion: 
The lymphovascular invasion is defined as that the presence of tumor 
mass within any space lined by endothelial cells and adherence of tumor 
cells to the endothelial cells. When the depth of invasion is more, there is 
increased chance for the occurrence of lymphovascular invasion
(65)
. LVSI is 
associated with decreased survival rate, and  increased risk of recurrence. 
Parametrial involvement: 
The tumor spreads to the parametrium either by contiguous spread and 
to lesser extent from lymphatic spread. Survival rate of stage I and II cancers 
is 90% without parametrial involvement, which gets reduced to77% with 
parametrial involvement. Involvement of parametrium with tumor shows 
high incidence of lymphnode metastasis, blood vessel invasion, recurrence 
of tumor and increased mortality.               
Nodal status: 
The metastasis of  lymphnode depends on several factors like clinical 
staging, size of tumor, distance of stromal invasion, lympho vascular 
invasion and grade of tumor. As the stage progresses to stage III and IV, 
there is increased chance of developing lymphnode metastases.The cervical 
cancer spreads to obturator, paracervical and external iliac nodes. The 
presence of pelvic node metastasis carries worse prognosis. Rarely there is 
involvement of para-aortic and scalene lymphnodes and if present it 
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indicates dissemination of cancer.5 yr survival rate was observed to 
decreases in the presence of pelvic lymphnode. 
AGE OF PATIENT: 
Females under 30 yrs of age  ,usually found to have better survival 
than elderly patients. But if they are compared to the clinical staging, there is 
difference in the survival rate. The younger females have worse prognosis , 
when they have higher stage at the time of diagnosis
(66)
.  
MOLECULAR GENETICS: 
In the pathogenesis of cervical carcinoma there are three major 
components, two of them related to the role of human papillomaviruses 
(HPV). First, the effect of viral E6 and E7 proteins. Second, the integration 
of viral DNA in chromosomal regions associated with well known tumor 
phenotypes. Some of these viral integrations occur recurrently at specific 
chromosomal locations, such as 8q24 and12q15, both harbouring HPV18 
and HPV16. And third, there are other recurrent genetic alterations not 
linked to HPV. Recurrent losses of heterozygosity (LOH) have been detected 
in chromosome regions 3p14–22, 4p16, 5p15, 6p21–22, 11q23, 17p13.3 
without effect on p53,18q12–22 and 19q13, all of them suggesting the 
alteration of putative tumor suppressor genes not yet identified. Recurrent 
amplification has been mapped to 3q+ arm, with the common region in 
3q24–28 in 90% of invasive carcinomas. The mutator phenotype, 
microsatellite instability, plays a minor role and is detected in only 7% of 
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cervical carcinomas. The development of cervical carcinoma requires the 
sequential occurrence and selection of several genetic alterations. The 
identification of the specific genes involved, and their correlation with 
specific tumour properties and stages could improve the understanding and 
perhaps the management of cervical carcinoma. 
The LOH means that a particular DNA region has been lost, and 
therefore, if this loss is recurrent, then it is considered significant. LOH is 
generally thought of as an intermediate step in the inactivation of tumour 
suppressor genes, such as p53or RB.  Inactivation of TP53 appears to play a 
key role in the development of malignancy in  HPV infection. 
TP53 inactivation is important in the progression from intraepithelial 
to invasive neoplasia
(67-69)
. Its reactivity is seen in both in situ lesions and 
invasive adenocarcinoma. It is absent in villoglandular adenocarcinoma  and 
in minimal deviation adenocarcinoma. 
FHIT ( fragile histidine triad) gene abnormality , including loss of 
heterozygosity, homozygous deletions and  aberrant transcripts , are 
common in cervical carcinomas. This gene  abnormalities have been found 
in both  CIN and invasive carcinoma. 
Monoclonality is seen in early invasive carcinoma and in nearly all 
cases of  high grade CIN found   to be monoclonal. 
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Recurrent amplifications and chromosome gain: 
Gene amplification and chromosome gain are two different 
mechanisms by which a tumour cell can increase a gene dosage. It has been 
found that fivefold or more amplifications were found for MYCL1, 
SEA,CCND1,BCL1and GLI genes, HRAS and HER2/neu. H ER2/ neu cases 
also showed rearrangement of the 17q11.2–12 band, suggesting a possible 
damage of this gene. Overexpression of ERBB2 gene has been previously 
reported in 60% of the cases studied (Pinion et al, 1991).ERB2/neu 
amplification has been observed in other carcinomas, including breast and 
ovary (Mitra et al, 1994b) 
Prognostic biomarkers: 
1. Ki 67 
Ki-67 is a proliferative marker .In normal conditions,it is usually present 
in the supra basal cells, overlying the basal cells of the normal cervical 
epithelium. If this marker is expressed in the superficial layer of cervix, it 
indicates  presence of infection of  HPV and related intraepithelial lesion. 
This is expressed in LSIL, HSIL and carcinoma. Increased expression of Ki-
67 is associated with poor prognosis. 
2. p16: 
p16 is an inhibitor of kinase which is cyclin-dependent. This marker is 
highly reliable  and its expression is related to infection caused by HPV of  
high risk and intermediate risk. This is absent in low risk HPVinfection.  
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1. Strong positive staining  is seen in HPV infection produced by 
intermediate group and high risk strain 
2. Weak staining  is seen in epithelium with mild atypia 
3. Staining in superficial cells and koilocytes is seen in HPV of low risk 
type. 
4. Focal strong staining is seen in columnar epithelium lining  the 
endocervix 
3. COX-2 
Cycloxygenase 2 (COX-2)  is an enzyme that is involved in the 
formation of prostaglandins from arachidonic acid. It is expressed in 
angiogenesis and thus increased in metastasis. In carcinoma cervix , the 
expression of COX-2 indicates poor prognosis
(70)
.In HPV- 16 infection ,E6 
and E7 oncoprotein through epidermal growth factor receptor regulates the 
transcription of COX-2 
4. CD 31 
It is an angiogenesis marker and its increased expression is associated 
with poor prognosis. 
5. HER-2-Neu 
HER2neu is the human epidermal growth factor receptor 2. This 
marker is found to be expressed in  many tumors including 
breast,endometrium, ovary, stomach, oesophagus and cervical cancer. It 
indicates progression of tumor and is usually associated with poor 
prognosis
(71)
. In studies , it was found that HER2 was expressed in varying 
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degrees upto 76% of cervical cancers. Many  clinical trials have been done 
using HER2 inhibitors  to cancer cervix patients. In recent studies, it was 
found thatHER2 expression did not correlate with the response of tumor , 
when treated with EGFR inhibitor.    
6. D2-40 positive 
Endothelial cells of lymphatic vessels express this marker .By 
counting  D2-40 positive vessels , we can assess the  lymphatic vessel 
density in the tumor. It has been observed that high expression of this marker 
is related to lymphnode metastasis and high tumor stage and thus indicates 
poor prognosis in cervical cancers
(72)
. 
7. C-myc expression 
8. LRIG 1 
Leucine rich repeats and immunoglobulin like domainsI(LRIG1) 
restricts signaling of growth factor  by increasing ubiquitylation and also by 
EGFR degradation .It also inhibits the action of oncogenes Met or Ret. 
The expression of  LRIGI  indicates favourable prognosis
(73)
, as it 
inhibits the growth factors and thus limiting the tumor progression. 
9.CD 4 positive lymphocytes 
Infiltration of CD4 positive lymphocytes of tumor cells indicates 
better survival. Its expression is associated with good prognosis.  
LRIG-1 and CD-4 lymphocytes are indicators of good prognosis, if 
they are present. All others are poor prognostic factors Cyclin- E is an 
another  marker  that indicates infection by human papilloma virus.   
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IMMUNOHISTOCHEMISTRY: 
IHC is a technique in which the antigen of interest in the particular 
tissue is detected by recognition of antigen- antibody complex. Progression 
of the tumor makes it more poorly differentiated, and the categorization of 
the tumor into specific types by histopathological techniques becomes very 
difficult. These  tumors  are histologically classified as undifferentiated, 
anaplastic , or small cell carcinoma. For clinicians ,it is very important to say 
whether the tumor belongs to epithelial, mesenchymal or of lymphoid cell of 
origin
(74)
 ,as their mode of treatment varies depending on the diagnosis. 
Immunohistochemistry is referred to as brown revolution. 
Immunohistochemistry helps the pathologists to fit the tumor, that has been 
classified as undifferentiated in histology , into a specific histogenetic 
origin.The subtyping of tumor is essential as it indicates prognosis and also 
thereby direct the clinicians to a targeted therapy against the particular 
tumor
(75)
.   To treat the patient adequately, it is essential to diagnose 
histologically and to categorize the tumor into its subtype. Histological 
diagnosis becomes difficult in certain tumors because of its varying 
presentation and undifferentiated feature in histology. Such tumor accounts 
for about 5-10% of all diagnosed tumors
(76)
. In such malignancies , advanced 
recent technologies play an important role. Among such technologies, 
immunohistochemistry is the method commonly utilized.  
Immunohistochemistry  identifies the particular antigen of interest ,for 
example HER2, or p53 ,by the formation of antigen antibody complex.It 
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seeks to exploit the specificity provided by the binding of an antibody with 
its antigen at a light microscopic level. IHC has a long history, extending 
more than half a century from 1940, when Coons developed an 
immunofluorescence technique to detect corresponding antigens in frozen 
tissue sections.
(77)
 
IHC has been used for the identification and demonstration of both 
prognostic and predictive markers. The basics of  IHC are similar to that of  
histochemistry and it is not an alternative for histochemistry but actually it 
act as a valuable adjunct. As emphasized by pioneers in this field of 
functional morphology, “the object of all staining is to recognize 
microchemically the existence and distribution of substances which we have 
been made aware of macrochemically
(78)
. 
The basic  critical principle of IHC, as with any other special staining 
method, is a sharp visual localization of target components in the cell and 
tissue, based on a satisfactory signal-to-noise ratio. Amplifying the signal 
while reducing non-specific background staining (noise) has been a major 
strategy to achieve a satisfactory result that is useful in daily practice. 
Antibody molecules are proteins; thus any rigid part of an antibody 
molecule may itself serve as the antigenic determinant to induce an antibody. 
IHC techniques exploit the fact that immunoglobulin molecules can serve 
both as antibodies and as antigens . Evaluation of an antibody for use in IHC 
53 
 
is based on two main points: the sensitivity and the specificity of the 
antibody-antigen reaction for IHC.  
The development of the hybridoma technique provided an almost 
limitless source of highly specific antibodies. Monoclonal antibodies do not 
guarantee antigen specificity; however, since different antigens may share 
similar or cross-reactive epitopes, the “practical” specificity reflected by IHC 
is excellent for most monoclonal antibodies. In contrast, a “polyclonal 
antibody” is an antiserum that contains many different molecular species of 
antibody having varying specificities against the different antigens (or 
antigenic determinants) used to immunize the animal. 
It is important to remember that polyclonal antibodies may also 
include varying amounts of antibodies to a whole range of antigens 
(including bacteria and viruses) that the immunized animal encountered 
before its use as a source of antibody. As a result, polyclonal antibodies 
often give more non-specific background staining in slides than encountered 
using monoclonal antibodies. 
Comparison of sensitivity and specificity between polyclonal and 
monoclonal antibodies indicates that polyclonal antibody may be more 
sensitive but less specific than monoclonal antibody. The reason may be that 
polyclonal antibody (actually a composite of many antibodies) may 
recognize several different binding sites (epitopes) on a single protein 
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(antigen), whereas a monoclonal antibody recognizes only a single type of 
epitope. 
Background staining of tissues that may be due to nonspecific 
antibody binding or to the presence of endogenous enzymes. Background 
staining should be blocked to get good results.  Non-specific antibody 
binding is due to polyclonal antibody, because multiple “unwanted” 
antibodies may exist in the antiserum. Preincubation with normal serum 
usually reduces these kinds of non-specific binding.Blocking endogenous 
enzyme activity is also important. Any residual activity of these endogenous 
enzymes must be abolished during immunostaining in order to avoid false-
positive reactions Peroxidase activity is present in a number of normal and 
neoplastic cells, including erythrocytes, neutrophils, eosinophils, and 
hepatocytes.  
When performing an immunohistochemical study in tissues rich in 
blood cells, such as bone marrow, it is recommended that a“peroxidase-
blocking” step be used, coupled with a“substrate control” (i.e., a section 
treated only with the hydrogen peroxide–chromogen mixture to visualize the 
extent of endogenous peroxidase activity).  
Otherwise, alternative methods, such as alkaline phosphatase, glucose 
oxidase, or immunogold labeling, may be used to avoid the possibility of 
confusion with any endogenous enzyme activity.  
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The blocking of endogenous enzymatic activity must be carried out 
before the addition of enzyme-labeled secondary reagent; otherwise, the 
enzyme label is also inactivated by the blocking procedure, resulting in a 
false- negative result. Antibody molecules cannot be seen with the light 
microscope or even with the electron microscope unless they are labeled or 
flagged by some method that permits their visualization. Essentially, 
detection systems attach certain labels or flags to primary or secondary 
antibodies in order to visualize the target antibody antigen localization in the 
tissue sections. A variety of labels or flags have been used, including 
fluorescent compounds and active enzymes that can be visualized by virtue 
of their property of inducing the formation of a colored reaction product 
from a suitable substrate system. The detection includes following methods 
like direct conjugate – labeled  antibody method, indirect or sandwich 
procedure, unlabeled antibody methods which includes enzyme bridge 
techniques, peroxidase-antiperoxidase method, biotin- avidin method, 
Avidin –biotin conjugate procedure, biotin-strepavidin system.  
Other methods include Alkaline phosphatase label, double stains, & 
polyvalent detection system which has alkaline phosphatase –antialkaline 
phosphatase method, and polymer based labeling , basic 2 step method, 
tyramine signal amplification method, titration of primary antibody and 
detection method.  
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After detection of antigen-antibody complex, amplification is done. 
This is classified into three methods: Pre amplification, Detection 
amplification, Post detection amplification.  
Pre amplification includes antigen retrival. Antigen retrival is done by 
applying high temperature, formalin fixed antigen is retrieved. Following 
techniques are  
Used: 
1. Water bath methods 
A. conventional water bath heating 
B. Dako PT link (Automated) 
2. Pressure cooker heating 
3. Autoclave heating 
4. Microwave oven heating 
5. Proteolytic pretreatment 
6. Combined proteolytic pretreatment & HIER( heat induced epitope 
retrieval) 
7. Combined deparaffinisation & target retrieval. 
The composition and PH of the buffer are crucial for optimal 
retrieval.Commonly used buffer is citrate buffer . Other high PH buffer are 
also being used. 
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Detection amplification is by  
A. Multistep detection system- PAP, ABC, APAAP, BSA 
B. Stepwise amplification 
        C, Polymeric and polylabelling amplification 
Post detection amplification is by 
A. Enhanced DAB by metal, imidazole & sba on CARD 
B. Anti- end product 
C. Gold/silver enhancement method 
After this , chromogen ( colour producing substrate system) is added to 
impart colour to the antigen antibody complex. Usually DAB is used, with 
horseradish peroxidase and gives brown colour. 
Then counterstain with hematoxylin and mounting as usual routine 
procedure. 
There are standardized procedures for immunohistochemical 
staining,laid by Ad-  Hoc committee.  
Recommendations for Improved Standardization of 
immunohistochemistry by the Ad-Hoc Committee110 Recommendation. 
1. Fix all specimens promptly in 10% neutral buffered formalin. 
2. Fix and process resections and core biopsies in an identical manner. 
3. Only use 10% neutral phosphate buffered formalin. 
4. Note that fixation is 8 to 72 hours for both core biopsies and resections. 
5. Use formalin, not alcohol, to fix cytology specimens for ER assay. 
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6. Use conventional tissue processors to process breast tissue. 
7. Ensure that the first formalin containers on the tissue processor are 
always newly replenished. 
8. Ensure that tissue processor fluids do not exceed 37°C. 
9. Be sure that paraffin in the tissue processor does not exceed 60°C. 
10. Record and document fixation times in your report. 
11. Use in vitro diagnostic kits that employ clone, 6F11, 1D5, or SP1. 
12. Include positive and negative controls with each batch run. 
13. Employ a threshold for positive result of 1% positive cells. 
14. Report semi-quantitation, tabulating the intensity (0, 1+, 2+, 3+) and 
percent of positive cells. 
In this study, Her2 neu is taken as prognostic marker in cervical 
carcinoma, which is identified by immunohistochemistry.    
HER 2 NEU: 
HER2 is the Human EGFR-2, which belongs to HER family. The gene 
encoding HER2 is located on chromosome 17 and is a member of EGF/erbB 
growth factor receptor family. 
The four members of the human epidermal growth factor receptor  
(HER) family: HER1 (EGFR, erbB1), HER2(erbB/neu), HER3 (erbB3) and 
HER4 (erbB4) are transmembrane tyrosine kinases, type I receptor, which 
take part in the regulation of cell proliferation, adhesion, migration and 
differentiation 
(79)
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Receptor activation and signal transduction act through homo-  and  
heterodimerisation. The formation of various dimeric pairs is dependent on 
the affinity between the different receptors and the concentration of both 
ligands and receptors
(80)
. The specific pattern of the heterodimeric pairs 
seems to modulate the intracellular response. Over expression of HER2 
recptors results in receptors transmitting excessive signals for cell 
proliferation to nucleus. This may lead to more aggressive growth of the 
transformed cell. Data supports the hypothesis that the HER2 transformed 
cells directly contribute to the pathogenesis & clinical aggressiveness of 
tumor that overexpress HER2. 
Receptor overexpression, especially of HER1 and HER2 has been 
associated with malignant potential and poor prognosis in various tumors
(81)
.  
These findings led to the development of specific antibodies targeting 
HER1 and HER2 for modern anticancer therapies . The development of pan 
HER inhibitors are hoped to further enhance the anti-tumor effects. In breast 
cancer as well as in other tumors, the anti-HER2 antibody trastuzumab 
(HerceptinTM,R) significantly improves survival, the strong anti-tumor 
activity being restricted to HER2-overexpressing tumours . 
  
60 
 
In carcinoma cervix, there are conflicting results regarding the 
frequency of HER2 expression, its prognostic consequence and consequently 
its value as a potential therapeutic target. Regarding the role of the other 
EGF receptors in cervical cancer, even more controversies exist. The aim of 
this study, is  to investigate the expression pattern of  HER2 and the 
influence on prognosis ,focusing on  carcinomas of  the uterine cervix.HER2 
Protein over expression is determined by membrane staining intensity and  
the slide evaluation should be performed using light microscope. 
 
TABLE no:3 HER2 scoring is done as follows: 
Score to 
report 
HER2 expression 
assessment 
Staining pattern 
0 Negative No staining is observed or membrane 
staining  is observed in <10% of tumor cells 
1+ Negative Faint / barely perceptible membrane staining 
is detected in >10% of tumor cells. The cells 
exihibt incomplete membrane staining  
2+ Weakly positive 
( equivocal) 
Weak to moderate complete membrane 
staining is observed in>10% tumor cells 
3+ Strongly positive A strong complete membrane staining is 
observed in > 10% of tumor cells 
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MATERIALS AND METHODS 
STUDY LOCATION: 
          The study was conducted at Department of Pathology, Tirunelveli 
Medical College.                 
STUDY PERIOD: 
            The study was conducted prospectively from 2012 to 2014. 
SAMPLES: 
INCLUSION CRITERIA: 
          1. Cervical biopsies diagnosed as carcinoma cervix. 
          2. Hysterectomy specimen diagnosed as carcinoma cervix. 
EXCLUSION CRITERIA: 
1. Other cervical biopsies diagnosed as Inflammatory conditions, 
benign Lesion. 
2. Cervical biopsies diagnosed as carcinoma in situ and mesenchymal 
lesion. 
3. Hysterectomy specimens of causes other than carcinoma cervix. 
SAMPLE SIZE:  
                100 cases of carcinoma cervix. [Annexure-6] 
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METHODOLOGY: 
DATA COLLECTION: 
The data of patients age, complaints, clinical staging, and other 
clinical data   including lymphnode status and parametrial extensions are 
obtained from the  pathology records and from case sheet of the patients. The 
data are recorded in a  format(Annexure 1) 
PROCESSING OF SPECIMEN:         
              Cervical biopsy specimen and hysterectomy specimens received 
were fixed in 10% formalin and processed routinely. 
GROSSING: 
             Biopsy  specimens were presented in toto and in hysterectomy 
specimen, cervix was carefully sectioned to include endocervix and 
ectocervix.  Sections of 4-5µ thickness were cut and stained with 
Haematoxylin & Eosin 
STAINING TECHNICQUE: 
         Annexure4 
The slides are studied under light microscopy and the data are 
recorded. Then the  sections are subjected to Immunohistochemical staining. 
IMMUNOHISTOCHEMICAL EVALUATION:                       
Immunohistochemistry is performed on 3-4m-thick sections taken on 
poly-L-lysine-coated slides. Antigen retrieval was performed by heating the 
sections in citrate-buffer at pH 6.0 using pressure cooker. Rabbit Monoclonal 
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antibody (Thermo Fisher Scientific  Laboratories) is used to bind with 
primary antigen and is detected by adding secondary antibody conjugated 
with horse radish peroxidase – polymer and diaminobenzidine substrate. In 
this study , HER2neu antigen of  Thermofisher laboratory products is used. 
PROCESSING FOR IMMUNOHISTOCHEMISTRY 
• 3µm thickness sections were cut using microtome from the selected 
paraffin blocks. 
• The sections are taken in poly L-lysine coated adhesive slides.The 
slides are incubated at 60 c for 1 hour 
• The slides are subjected to 2 changes of xylene , 5  minutes each for 
deparaffinization. 
• They are then transferred to absolute alcohol for 5 minutes followed 
by  80% and 70% alcohol for 5 minutes to rehydrate the tissue 
sections. 
•  Tissue sections are then placed in running tap water for 5 minutes and 
washed in distilled water 
• Antigen  retrieval was performed using pressure cooker in citrate 
buffer         
• Then the sections are cooled to room temperature and the slides are 
washed with distilled water 
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• Endogenous peroxidase activity is removed by incubating the tissue 
sections with enough drops of 3% peroxide block in a humidity 
chamber for 5minutes.The sections are then washed in TRIS  wash 
buffer. 
• Primary antibody (Her2 neu) is then added over the tissue sections  
and incubated for 30 minutes . 
• The tissue sections are then washed in TRIS wash buffer. 
• Followed by that primary amplifier is added for 15 minutes to enhance 
the process of primary antibody which is then washed in TRIS  wash 
buffer 
• Secondary antibody is added and incubated for 20 minutes  and then 
washed with TRIS  wash buffer 
• DAB chromogen (1ml DAB buffer +1 drop DAB chromogen) is then 
added over the tissue and incubated for 4 minutes and then washed 
with 2 changes of distilled water. 
• Counterstaining was done with haematoxylin for 30 seconds and 
washed in running tap water. 
• Dehydration is done by 2 changes of   100 % alcohol. 
• Mounting is done by DPX mountant and observed under microscope. 
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BUFFER PREPARATIONS 
1. Citrate buffer 
               Citric acid             -  1.92 gms 
               Distilled water   -  1000ml 
Ph is adjusted to 6.2 with 1N NaoH 
2. Tris wash buffer 
                 Tris               -    0.605 gm   
             Sodium chloride - 8 gm 
              1 N Hcl                 - 4ml 
              Distilled water -  1000 ml 
PRECAUTIONS 
1. The glassware’s used should be dry and clean. 
2. All the buffers used should be prepared fresh  and the  p H should be 
adjusted according to the preferred p H. 
3.  The staining procedures are never allowed to dry so they are 
performed under a humidity chamber. 
4. DAB  chromogen should be handled and disposed carefully as it is a 
carcinogen. 
5. Primary,secondary antibody, DAB chromogen, peroxidase block, 
Amplifier,everything should be stored at 4-6ºC 
While performing IHC every batch should have a positive control 
slide. Then the slides are counterstained with Mayers Hematoxylin. 
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SCORING OF HER2/neu STAINING: 
Her2/neu positivity is graded as per ASCO guidelines.A positive 
reaction was taken as crisp golden brown membranous and cytoplasmic 
staining. Intensity of staining was graded under ASCO scoring system as 
strong, complete membrane staining in more than 10% of malignant cells 
(3+); week to moderate complete staining in more than 10% of malignant 
cells (2+); no or fewer than 10% cells staining (0 to 1+) respectively. 
STATISTICAL ANALYSIS:
 
  
Statistical analysis of data was performed using statistical package for 
social  science software version 11.5 . HER2/neu expression  and  its 
correlation with various  factors was calculated using Pearsons  Chi-square 
test.  P value <0.05 was taken as statistically significant.                          
 ETHICAL CONSIDERATION: 
The study was conducted after obtaining approval from the  
Institutional Ethical Comittee of Tirunelveli Medical College, Tirunelveli. 
The  study included cervical biopsies and hysterectomy specimens submitted 
for histopathological examination to the Department of Pathology, 
Tirunelveli Medical College from 2012 to 2014. 
 
 
 
 
 OBSERVATION AND RESULT
Study design: 
A total of 100 cases 
cervical biopsies or hysterectomy specimen
Among these 100 cases
cases were adenocarcinoma
was adenosquamous carcinoma
Table 4: Distribution of histological 
Types of carcinoma
Squamous cell carcinoma
Adenocarcinoma 
Small cell carcinoma
Adenosquamous carcinoma
 
IHC for HER2/neu oncoprotein was done in these 100 cases.
Chart no 1: Distribution o
21
Squamous cell carcinoma
Small cell carcinoma
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S: 
of  carcinoma of cervix obtained  as either 
s were included 
, 75 cases were  squamous cell carci
(21%), 3 cases were small cell carcinoma
. 
types of carcinoma cervix: 
 Total no of cases(n=100)
 75 
21 
 3 
 1 
f carcinoma cervix cases among histological types
75
3
1
Adenocarcinoma
Adenosquamous carcinoma
in the study. 
noma(75%) , 21 
(3%),  1 
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This chart no 1 shows the distribution of cases between histological 
types of carcinoma cervix. Among 100 cases, 75 were squamous cell 
carcinoma, 21 were  adenocarcinoma, 3 were small cell carcinoma, and 1 
was adenosquamous  carcinoma.   
AGE WISE DISTRIBUTION OF CASES: 
Table 5:  Distribution of  cases according to age group in carcinoma 
cervix 
Age group of patients Number of cases(n=100) 
30-40yrs 11 
41-50yrs 22 
51-60yrs 30 
61-70yrs 30 
71-80yrs 7 
 
When cases were categorized based on age group,30 cases fall under 
51-60yrs of  age, another 30 cases were of 61-70 yrs, 22 cases were of 41-50 
yrs, 11 cases fall  under 30-40 yrs, 7cases were of 71-80yrs. 
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Table 6: Distrbution of HER2/neu expression among age wise 
distribution of cases of carcinoma cervix: 
Age group 
No of HER2 positive 
cases(n=17) 
30-40yrs 0 
41-50yrs 5(22.7%) 
51-60yrs 6(20%) 
61-70yrs 5(16.6%) 
71-80yrs 1(14.2%) 
 
DISTRIBUTION OF HER2/neu EXPRESSION IN CARCINOMA 
CERVIX: 
Among  100 cases of carcinoma cervix, HER2/neu expression is seen 
in 17 cases. Out of this 17 cases , 16 cases are squamous cell carcinoma and 
1 case is of small cell carcinoma.  
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Table 7: Distribution of HER2/neu expression among histological types 
of carcinoma cervix 
Type of carcinoma 
No of HER2/neu 
positive cases (n=17) 
Squamous cell carcinoma 16(94.11%) 
Small cell carcinoma 1(0.05%) 
Adenocarcinoma  0 
Adenosquamous carcinoma 0 
 
SQUAMOUS CELL CARCINOMA: 
In 75 cases of squamous cell carcinoma, there were 23 cases of well 
differentiated carcinoma (30.6%),48 cases were(64%) moderately 
differentiated, and 4 cases were(5.33%)   poorly differentiated carcinoma. 
These data are mentioned in the following  Table 8 
Table 8: Distribution of Histological grades of Squamous cell 
carcinoma: 
Grades  of squamous cell 
carcinoma(n= 75) 
Number of cases 
Well differentiated carcinoma 23(30.6%) 
Moderately differentiated 
carcinoma 
48(64%) 
Poorly differentiated carcinoma 4(5.33%) 
 
 Chart no:2  Distribution of 
Among 75 cases of squamous cell carcinoma ,
squamous cell carcinoma
HER2 positive  squamous cell carcinoma,  
moderately differentiated, 3 cases
(25%) of poorly differentiated 
following  Table 9  
Table 9: Distribution of 
cell carcinoma. 
Grades  of squamous cell 
carcinoma 
Well differentiated 
carcinoma(n=23)
Moderately differentiated 
carcinoma(n=48)
Poorly differentiated 
carcinoma(n=4)
 
64%
71 
cases among grades of squamous cell 
carcinoma 
 16 cases
 were positive for HER2/neu oncoprotein.
12 cases(25%)
(13%) were of well differentiated, 1 case 
carcinoma. The data are
 HER2neu expression in grades of squamous 
HER2 positive 
cases (n=16) 
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Among 75 cases of squamous cell carcinoma, 35 cases were negative 
for HER2/neu (46.6%), 24 cases scored 1+(32%), 8 cases were 2+(10.6%), 8 
cases were 3+(10.6%).( details in Table 10) 
Table  11: Correlation of HER2/neu expression with grades of squamous  
cell carcinoma 
Grades of squamous cell 
carcinoma 
HER2 positive 
cases (n=16) 
HER2 negative cases 
Well differentiated (n=23) 3(13.04%) 20 
Moderately differentiated 
(n=48) 
12(25%) 36 
Poorly differentiated (n=4) 1(25%) 3 
 
Chi square test  = 1.3584 ; P value is 0.50702.The result is not 
significant From the above table , it is undersood that there is no significant 
correlation of  HER2/neu expression with histological subtypes of squamous 
cell carcinoma.  HER2/neu expression  is about 13% in well differentiated 
type, 25% in moderately differentiated type and 25% in poorly differentiated 
type. 
 Chart no 4: Distributi
grades
SMALL CALL CARCINOMA
Among 100 cases, 3 cases were small cell 
1 case was positive for  HER2 /neu protein(33.33%) and score was 2+.
Table 12 : Distribution of small cell carcinoma with its HER2/neu 
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ADENOCARCINOMA: 
Among 100 cases, 21 cases were adenocarcinoma. In this 21 cases , 
HER2/neu was  1+ in 1 case and all other cases scored negative. According 
ASCO guidelines, 1+ was considered as negative. So , as a whole 
Adenocarcinoma  case were negative for HER2 /neu expression. 
Table 13: Distribution of Adenocarcinoma with its HER2/neu 
expression and scoring: 
Type of 
carcinoma 
Total no of 
cases 
HER2 positive 
cases 
Score of 
HER2 
Adenocarcinoma 21 0 Negative 
 
ADENOSQUAMOUS CARCINOMA: 
Among 100 cases, only 1 was adenosquamous carcinoma . This  one 
case was negative for HER2 /neu expression. 
Table 14: Distribution of Adenosquamous carcinoma with its HER2/neu 
expression and scoring: 
Type of carcinoma 
Total no of 
cases 
HER2 positive 
cases 
Score 
Adenosquamous 
carcinoma 
1 0 Negative 
 
 
  
 STAGING OF CARCINOMA
According to FIGO STAGING
categorized as follows:
Table 15: Distribution of
cervix: 
FIGO Stage
Stage I
Stage II
Stage III
 
In this 100 cases, 17 cases were positive for HER2 /neu marker. 
Among this 6 cases  
II(18,18%) were positive and 7 cases of stage III( 50%) were positive.
Chart no:5  Distribution of cases of cancer cervix among clinical stage
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Table 16: Distribution of HER2/neu expression in clinical staging of  
carcinoma cervix: 
Clinical staging Total cases HER2 positive 
cases(n=17) 
Stage I 64 6(9.37%) 
Stage I 22 4(18.18%) 
Stage III 14 7 (50%) 
Stage IV 0 0 
 
Table 17: Correlation of  HER 2/neu expression with clinical staging of  
carcinoma cervix  
Clinical 
staging 
Total cases  
HER2 
positive 
cases(n=17) 
 
HER 2 
negative 
Stage I 64  6(9.37%)  58 
Stage II 22  4(18.18%)  18 
Stage III 14  7(50%)  7 
Stage IV 0  0  0 
 
CHISQUARE VALUE – 13.464 ; P VALUE – 0.0011 
The result is significant 
Table no:17 shows the distribution of HER2/neu positive cases in 
relation to various clinical staging. From the above table it is clear that, stage 
 III cases had increased HER2/neu expression of about 50% positivity .
there is a strong correlation exist between H
staging. 
Chart no:6  Association
It shows the HER2/neu expression increase as the staging of  cancer 
increases. 
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LYMPHNODE METASTASES: 
Among 100 cases , there were 9 cases showed lymphnode metastases. 
9 cases were of squamous cell carcinoma only.1 case was well differentiated 
carcinoma, 7 cases were of moderately differentiated carcinoma and 1 case 
was of poorly differentiated carcinoma. 
Table 18: Distribution of lymphnode metastasis in carcinoma cervix: 
Type of carcinoma Lymph node positive cases(n=9) 
Squamous cell carcinoma 9(100%) 
Adenocarcinoma  0 
Adenosquamous carcinoma 0 
Small cell carcinoma 0 
 
Table 19: Distribution of  Lymphnode metastasis in squamous cell 
carcinoma of cervix: 
 
Lymphnode metastases in grades 
of  squamous cell carcinoma 
No of cases(n=9) 
Well differentiated carcinoma 1(11.11%) 
Moderately differentiated carcinoma 7(77.7%) 
Poorly differentiated carcinoma 1(11.11%) 
 
 
 Out of the total 100 cases  , 9 cases  were positive for lymph node 
metastasis , and out of which 5 cases were positive for HER2 /neu 
oncoprotein (55.55%) and all of them  belonged to moderately differentiated 
squamous cell carcinoma
Chart no :7  Percentage of Lymph node metastasis in squamous cell 
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Table 20: Correlation of HER2/neu expression with Lymphnode 
metastasis in carcinoma cervix: 
Lymphnode 
metastasis 
 
 
Total 
cases 
HER2 
Positive 
cases 
 
HER2 
negative 
cases 
P value 
       
Present   9 5(55.55%)  4 <0.05 
      
Absent   91 12(13.1%)  79  
 
 
CHI SQUARE TEST- 13.379 ; P VALUE – 0.001. The result is significant as P< 0.05 
The above Table no:20 shows the association of HER2 /neu 
expression with  lymphnode metastases . Totally there were 9 cases with 
positive lymph node metastases. Among this 9 cases , 5 cases showed 
HER2/neu expression(55.55%).  
Based on Pearsons chisquare test, P value is significant and so there is 
correlation exist between HER2/neu expression and lymph node metastasis 
in carcinoma cervix. 
As all the 5 lymphnode positive cases belonged to squamous cell 
carcinoma, moderately differentiated type, the association of HER 2/neu 
positivity  in squamous cell carcinoma in  lymph node metastasis was 
studied and correlated. 
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Table 21: Correlation of HER2/neu expression with lymph node 
metastasis in  squamous cell carcinoma in cervix: 
Lymphnode 
metastasis 
 
 
Total 
cases 
 HER2positive 
HER2 
negative 
P 
value 
       
Present   9  5(55.55%) 4 <0.05 
      
Absent   66  11 55  
 
 
CHI SQUARE TEST- 7.1372 ; P VALUE – 0.007. The result is significant as P< 0.05 
The above Table no:21  shows the association of HER2 /neu 
expression with  lymphnode metastases in squamous cell carcinoma . Totally 
there were 9 cases with positive lymph node metastases. Among this 9 cases 
of squamous cell carcinoma  , 5 cases of moderately differentiated carcinoma 
showed HER2/neu expression(55.55%). As the p value is significant, there is 
correlation between HER2/neu expressions with lymphnode metastasis in 
squamous cell carcinoma. 
 
 
 
 
 
  
Chart no: 8 Association
Chart no: 8 shows HER2 /neu expression in lymphnode metastases 
cases, diagrammatically. Among 9 cases of lymph node 
were positive for HER2/neu  (55.55%). Among 
there were 12 cases 
correlation between lymphnode metastases
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PARAMETRIAL EXTENSION: 
     Parametrial extension is defined as an irregular margin of cervix and soft 
tissue of the parametrium is more prominent, associated with either a mass 
of parametrium or loss of periureteral fat plane. The last criteria is a more 
diagnostic of parametrial extension.  
In this study, out of total 100 cases , 30 cases show parametrial 
extension. Among these 30 cases ,21 cases were of moderately differentiated 
squamous cell carcinoma, 3 cases were of well differentiated, 3 cases of 
poorly differentiated carcinoma, 1 case of adenocarcinoma, and 2 cases of  
small cell carcinoma. 
Table 22: Distribution of parametrial involvement in carcinoma cervix: 
Type of carcinoma 
Parametrial extension 
cases(n=30) 
Squamous cell carcinoma 27(90) 
Adenocarcinoma 1(3.33%) 
Small cell carcinoma 2(6.66) 
 
 
 
  
 
Chart no: 9 Distribution of parametrial extension in carcinoma cervix
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Table 23: Distribution of  parametrial extension in grades of squamous 
cell carcinoma:    
Subtype of squamous cell 
carcinoma 
Parametrial extension 
cases 
Well differentiated 3(11.11%) 
Moderately  differentiated 21(77.7%) 
Poorly differentiated 3(11.11%) 
 
Among 30 cases of parametrial extension, 10 cases were positive  for 
HER2 /neu marker. Out of 10 cases,8 cases were of moderately squamous 
cell carcinoma, 1 was of poorly differentiated, and 1 was of small cell 
carcinoma. 
Table 24: Distribution of  HER2/neu positivity  in parametrial extension 
cases of carcinoma cervix: 
Type of carcinoma HER2 Positive cases(n=10) 
Squamous cell carcinoma 9(90%) 
Small cell carcinoma 1(10%) 
 
     Association of HER2/neu positivity with parametrial extension  in total 
100 cases were made out.  
 
 Table 25: Correlation of  HER2/neu
extensions in carcinoma cervix
Parametrial 
extension 
 
 
Present   
Absent   
CHISQUARE TEST=8.103;
The result is significant
Table no:25 shows the association 
parametrial extension. There were about 30 cases  showing parametrial 
extension. Among this,  10 cases 
(33.33%). There was also significant correlation between parametrial 
involvement and HER2/neu expression.
Chart no: 10 Association of
cases of carcinoma cervix:    
parametrial extension
without parametrial extension
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The above chart shows HER2/neu expression in parametrial extension 
cases diagrammatically. Among 30 cases, 10 were positive for HER2/neu 
oncoprotein (33.33%). As there were 27 cases of squamous cell carcinoma  
having  parametrial  extension  and out of this 27 cases, 9cases of squamous 
cell carcinoma had HER2 /neu expression,(90%), their association was 
studied and correlated.  
 
Table 26:  Distribution  of   HER2/neu expression  in parametrial 
extension cases among grades of squamous cell carcinoma:  
 
 
Grades  of squamous cell 
carcinoma 
HER2 positive  cases in 
parametrial extension(n=9) 
Well differentiated Nil 
Moderately differentiated 8 
Poorly differentiated 1 
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Table 27: Correlation of HER2/neu with parametrial extension   
cases of squamous cell carcinoma: 
Tumor type- squamous 
cell carcinoma(n=75) 
Present Absent 
Parametrial  extension 27(90%) 48 
HER2 positivity 9 7 
 
P value is 0.132. the result  is not significant. Thus there is no 
correlation exist between HER2/neu expression with parametrial extension 
in squamous cell carcinoma. 
 
 
 
 
 
 
 
 
 
 
                                                     
 
 
 
 
 
 
FIG NO:6   - IHC staining of HER2/neu ; score : 3+ 
Neoplastic  squamous cells show strong  membranous staining of  HER2/neu in 
400x(score:3+) 
 
 
 
 
 
 
Fig no:7 IHC staining of HER2/neu- score: 3+; 400x 
Membranous staining of malignant squamous cells. Score- 3+;400x 
 
 
 
 
 
 
 
Fig no:8 IHC Staining of HER2/neu – score:2+; 400x 
Neoplastic squamous cells show less intense membranous staining .score: 2+, 
400x 
 
 
 
 
 
 
Fig no:9 IHC Staining of HER2/neu : score 2+; 400x 
Neoplastic cells with less intense membranous staining, and pleomorphic 
nuclei, and prominent nucleoli.( HER2 staining- SCORE 2+;   400x) 
 
 
 
 
 
 
    
Fig no:11 IHC staining of HER2/neu – score : negative; 400x 
This shows negative staining for HER2 in carcinoma cervix ; 400x. 
 
 
 
 
 
 
Fig no:12A: H&E stain- Well differentiated squamous cell carcinoma 
Malignant squamous cell infiltrating the stroma as finger like projections.-well 
differentiated ;(100x). 
 
 
 
 
 
 
 
FIG No 12 (B):  H&E: Well differentiated squamous cell carcinoma (400x) 
Cells Are Large, Polygonal , With Pleomorphic Vesicular  Nuclei, And 
Prominent Nucleoli. 
 
 
 
 
 
 
 
Fig no:18 H& E stain: Small cell carcinoma 
Malignant squamous cells are small, with nuclear molding – feature of small 
cell carcinoma.(100x) 
 
 
 
 
 
 
 
Fig no:15 H&E stain: Well differentiated carcinoma : 100x 
Squamous cell nest  with central necrosis. 
 
 
 
 
 
 
 
 
Fig no:17-  H&Estain:   Poorly differentiated carcinoma:(400x) 
Individual cells are large,  pleomorphic, and mitosis is seen. 
 
 
 
 
 
 
 
 
Fig no: 10  IHC staining of HER2/neu – score 1+; 400x 
Neoplastic squamous cells with weak membranous staining ; 400x 
 
 
 
 
 
 
 
Fig no:16 H&E stain: Individual cell keratinisation: 400x 
Individual cell keratinisation  is  seen. Feature of moderately differentiated 
squamous cell carcinoma. 
 
 
 
 
 
 
Fig no: 14:  H&E       Keratin pearls 
Feature of well differentiated carcinoma ;400x 
 
 
 
 
 
 
 
 
Fig no: 13 H&E stain: Keratin pearls 
Three keratin pearls in one field.H& E stain(100x)  
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DISCUSSION 
Carcinoma of  the  uterine cervix remains a major cause of mortality 
in women in the developing world including India(1). According to recent 
data provided by the Atlas of Cancer in India project by the ICMR , cervical 
cancer is the second most common cancer in women after breast cancer in 
most urban population  based registries in India(1), varying from 10.9 to 
65.4 amongst various registries  with an average incidence of around 25 per 
1, 00,000 women(1). 
Currently , one of the oncogenes, c-erb-2/HER-2 is thought to be 
associated with various tumors of the breast, ovary, endometrium, cervix, 
fallopian tube  etc and is being studied extensively.
 [82]
 The exact function of 
HER-2/neu gene product is still unknown but it has tyrosine kinase activity 
and is thought to function as receptor for growth-regulating molecule. 
Activation of  HER family members occurs through ligand and a 
dimer of the same monomer or other member of the HER family that are 
bound together . Once activation has occurred , tyrosine autophosphorylation 
of  cytoplasmic signal proteins transmit signals to the nucleus , thus 
regulating aspects of cell growth , division , differentiation and migration. 
Overexpression of HER2 receptors  results in  transmitting  excessive signals 
for cell proliferation to nucleus. This may lead to more aggressive growth of 
the transformed cell. HER2 transformed cells directly contribute to the 
pathogenesis and clinical aggressiveness of the tumor  that overexpress 
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HER2. The overexpression of HER2 is associated with poor prognosis, 
including recurrence of  the tumor  and  reduced overall survival. 
HER-2/neu over-expression or mutation results in quantitative and 
qualitative alteration in the membrane proteins which is the basis of its 
detection.
 [83],[84]
  Even though  clinical correlation had not been established, 
many series had suggested that amplification or over-expression of the 
oncogene might be a marker of poor prognosis in cancers of the ovary, 
endometrium, breast etc.
 [85],[86],[87]
 There were reports in the literature that 
HER-2/neu over-expression correlates with reduced benefit of adjuvant 
therapy as in cases of carcinoma breast with tamoxifen therapy.
 
 Many 
studies have shown that regression of HER-2/neu suppresses the malignant 
phenotypes of cancer cells over-expressing this oncoprotein, which may 
serve as an excellent target for developing anti-cancer agents specific for 
HER-2/neu over- expression.
 [88] 
HER-2   expression can be estimated either 
by immunohistochemistry or by fluorescent in situ hybridization (FISH). 
FISH can be used for doubtful  cases in IHC to confirm, HER2/neu 
expression. This combination is not necessary for low (0-1+) or high (3+) 
grades of immunohistochemical stain as the  correlation with gene 
amplification status is high.
  
 
With  reviewof the literature available, it was observed that the studies 
designed to examine HER-2 in lesions of the uterine cervix showed 
inconsistent results. HER-2 positive staining in invasive carcinoma cervix 
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ranged from 14-100% in various studies
(89,90,91)
. Similarly, large variability 
was also observed  in various types of carcinomas, lymph node metastasis 
and parametrial extension. Several articles on uterine lesions suggest HER-2 
positivity is directly related with higher grade and more aggressive tumor, 
and having poor prognosis.
,[92]
 There are also reports revealing that over-
expression/amplification of HER-2/neu is uncommon in invasive cervical 
carcinoma and expression of HER2/neu does not appear to be related to 
prognosis or treatment outcome. 
From the above studies, it was observed that controversy exists 
regarding the expression of HER-2 in various disorders of the uterine cervix. 
This study was planned to compare the expression of HER-2 in invasive 
cervical carcinomas among the women in this region of the country. 
In cervical carcinomas, amplification of the HER-2/neu gene has been 
found in 1.5% to 18% of the cases assessed by Southern blot, slot blot, 
polymerase chain reaction (PCR), or in situ hybridization
(89)
. The rate of  
expression of HER2/neu assessed by immunohistochemistry has ranged from 
9% to 42% 
(89)
. 
  In the carcinoma cervix, correlation between  overexpression and 
clinical stage or survival has been reported in some studies
(92)
 but not in  
others
(93)
.  
Nakano.T et al(1994)
(91)
 studied about prognostic significance of 
HER2 expression in advanced uterine cervical carcinoma and found that 
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HER2 positive staining was observed in cancer membrane and cytoplasm 
and the total positive rate was 43%.  
They associated with 5-yr survival rate, and compared with negative 
groups and found reduced survival in HER2 positive cases and therefore 
poorer prognosis.  
Multivariate analysis using Cox proportional hazards model showed 
that HER2 was an independent prognostic factor (P = 0.024).  
Berchuck A , et al(1990)
(90)
  studied about expression of epidermal 
growth factor receptor and HER-2/ neu in normal and neoplastic cervix , 
vulva  and vagina. They found that in squamous epithelia of the cervix, 
vulva, and vagina, epidermal growth factor receptor and HER-2/neu both 
were expressed most strongly by basal keratinocytes. Expression of both of 
these cell surface molecules decreased as cells underwent differentiation 
towards the mucosal surface. In contrast, both epidermal growth factor 
receptor and HER-2/neu were expressed throughout the entire thickness of 
the epithelium by undifferentiated squamous cells in squamous metaplasia, 
raised condyloma  and carcinoma in situ. Staining of 34 cases of vulval, 
vaginal, cervical lesions, 33 of these cancers for HER-2/neu was weak, 
although one patient who presented with distant metastases had strong 
staining for HER-2/neu. 
Fadare, Oluwole M.d ., et al(2004)
(94) 
found that immunohistochemical 
study of HER2 expression in tissue microarray containing 169 cases of 
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cervical carcinoma comprised of cancer staging Ia and Ib cases. Among this 
squamous cell carcinoma constitute about 110 cases, 36 were 
adenocarcinoma, 13 were adenosquamous carcinoma, neuroendocrine tumor 
were about 2 in number, adenocarcinoma with neuroendocrine 
differentiation were 2 in number, mixed squamous cell carcinoma was 1 in 
number.HER2neu expression was <1%. Rosy et al have noted , strikingly  
discrepant results regarding the frequency of HER2/neu overexpression 
ranging from <1% to 42%. Both  of them , had increased  HER2neu 
expression in small cell carcinoma.  
Nakano T et al (1994), found c-erbB-OncoProtein Expression(Cerb B-
OPE) was observed on the cell membrane of carcinoma cells. Positivity of 
CerbB-OPE, which  showed differences among histologic subtypes , in early 
cervical squamous cell carcinoma. 
Nidhi gupta et al ,(2009)
(95)
 observed in their study that  63% cases of 
carcinoma cervix showed definite membranous staining for c-erbB-2 
oncoprotein and these included squamous cell carcinoma (54.1%), 
adenocarcinoma (84.61%), adenosquamous carcinoma (100%) and CIN 
(60%). It was also observed that the positivity varied with differentiation and 
staging, lymph node metastasis and parametrial extension status. Poorly 
differentiated squamous cell carcinoma showed 80% positivity  whereas 
positivity was 87.5% and 100% in case of Stage-III and IV tumors . Cases 
with lymph node metastasis revealed 92.86% positivity whereas with 
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parametrial extension revealed 71.88% positivity. Out of 14 cases of lymph 
node metastasis, squamous cell carcinoma (11 cases) and adenocarcinoma 
(three cases) showed c-erbB-2 positivity rate of 90.9% and 100% 
respectively. There were 32 cases of parametrial extension of which HER-2 
was positive in squamous cell carcinoma (67.86%), adenocarcinoma (100%),  
adenosquamous carcinoma (100%) .  
The present study included 100 cases of cervical  biopsies and 
Abdominal hysterectomies which were staged by FIGO staging  from stage I 
b to IIIb. The histological subtypes comprised of 75 cases of squamous cell 
carcinomas,  21 cases of adenocarcinomas,3 cases of  small cell carcinoma, 
and 1 case of adenosquamous carcinoma . Among these cases, 17cases 
(17%) were found to be positive for HER2/neu expression.  
     
COMPARISON OF PERCENTAGE OF HER2/neu EXPRESSION  IN 
PRESENT STUDY WITH OTHER STUDIES: (Table 28) 
    Comparing the HER2positivity with other studies, it were seen that 
about 43% of cases showed positive for HER2 in Nakano.et al study
(91)
, <1% 
in Fadare.,et al study
(94)
,and  63% in Gupta .et al study
(95)
. Among these 
studies, present study have more similarities with Gupta.,et al study. 
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TABLEno:28  Comparision of % of  HER2 neu expression among 
different studies 
Name of study HER2 expression 
Nakano .et al (1994) 
(91) 
43% 
Fadre ., et al (2004) 
(94) 
<1% 
Gupta. et al (2009)
(95) 
 63% 
Present study 17% 
 
COMPARISON OF HER2 EXPRESSION IN HISTOLOGICAL 
TYPES OF CARCINOMA CERVIX : (Table 29) 
Among 17 cases, 16 cases of squamous cell carcinoma (21.33%) , and 
1 case (33%) of small cell carcinoma were positive for HER2 oncoprotein. 
The positivity rate varied with different hitological types, and with varying 
stages, presence of lymph node metastases, and parametrial extension.  
  Gupta. Et al got 54.1% positivity  in squamous carcinoma ,whereas 
present study showed 21.33% only,  in squamous carcinoma. It was 84.61% 
positivity in Adenocarcinoma and was 100% in Adenosquamous carcinoma 
in the study of  Gupta .et al. But the present study got no positivity in both 
adenocarcinoma as well as in adenosquamous carcinoma. 
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TABLE no 29: Comparison of  HER2 expression in histological types of  
carcinoma cervix between Gupta. Et al study and this study: 
Name of 
study 
Squamous 
cell 
carcinoma 
Adenocarcinoma 
Adenosquamous 
carcinoma 
Small cell 
carcinoma 
Gupta. Et al 
(2009)
(95) 
54.1% 84.61% 100 Nil 
This study 21.33% Nil Nil 33.33% 
 
In squamous  cell carcinoma, high positivity rate(25%)  was   for 
poorly differentiated  carcinoma and among other types of carcinoma, small 
cell carcinoma had  high positivity rate(33.33%). 
COMPARISON OF HER2/neu EXPRESSION IN GRADES OF 
SQUAMOUS  CELL CARCINOMA:( Table 30) 
         In the present study , HER 2/neu positivity in well differentiated 
carcinoma is 13.04%, moderately differentiated  carcinoma is 25%, and 
poorly differentiated carcinoma is 25%. In Gupta.et al study, the HER2/neu 
positivity in moderately differentiated carcinoma is 54.55%, and in poorly 
differentiated carcinoma is 80%. 
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Table  30: Comparison  of  HER2/neu expression in grades of Squamous 
cell Carcinoma of cervix between this study and Gupta.et al study: 
Name of  study 
Well 
differentiated 
carcinoma 
Moderately 
differentiated 
carcinoma 
Poorly 
differentiated 
carcinoma 
Gupta.et 
al(2009)
(95) 
0 54.55% 80% 
This study 13.04% 25% 25% 
 
The present study when compared with Gupta.et al study, it is seen 
that well differentiated carcinoma showed 13.04%, whereas it is negative in 
Gupta.et al study. There is increased expression of HER2/neu with higher 
grade. But in the present study , the expression is of same percentage (25%) 
in both moderately and poorly differentiated carcinoma . 
COMPARISON OF HER2/neu EXPRESSION IN CLINICAL STAGE 
OF CARCINOMA CERVX: (Table 31) 
      There was increased positivity rate in stage III( 50%) of cervical 
carcinoma,  followed by stage II (18%), stage I (9%). In the present study, 
stage IV  carcinoma was not included as the block was not available . In 
Gupta .et al study, highest HER2 positivity was for stage IV carcinoma 
(100%), followed by stage III (87.5%), stage II (72%), and stage I (48%). 
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TABLE no:31 Comparison of distribution HER2 expression in clinical  
stages  of carcinoma cervix in Gupta. Et al study this study:  
 
Name of 
study 
Stage I Stage II Stage III Stage IV 
Gupta .et al 
(2009)
(95) 
48% 72% 87.5% 100% 
This study 
9.37% 18% 50% Nil 
 
In both study , there is increasing order of HER2 expression as the 
stage of the cancer progresses , but in varying rates. 
The present study shows significant co-relation( p value- 0.0016)  
exists between  HER2 expression and stage of the tumor. Gupta .et al study 
also had significant p value(<0.05). 
COMPARISON OF HER2/neu EXPRESSION IN LYMPH NODE  
METASTATIC CASES OF CARCINOMA CERVIX: (Table 32) 
Lymphnode metastases were found in 9 cases which belongs to 
squamous cell carcinoma. Among this 9 cases, 5 cases( 55.55%) were 
positive for HER2 protein. In Gupta .et al  study , lymphnode metastasis 
were seen in 14 cases and among this ,13 cases were positive for HER2( 
92.86%).   
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TABLE no 32 :Comparison  of   HER2 expression in lymphnode 
metastatic case of carcinoma cervix  in Gupta . et al and present study. 
Name of study Total cases of lymphnode 
metastases 
HER2 
positivity 
Gupta .et al 
(2009)
(95)
   study 
14 13( 92.86%) 
Present study 9 5(55.55%) 
 
Thus in both study , there were increased expression of HER2 in 
lymphnode metastasis cases. 
COMPARISON OF HER2/neu EXPRESSION IN PARAMETRIAL 
EXTENSION CASES OF CARCINOMA CERVIX: (Table 33) 
There were 30 cases of parametrial  extension ,which comprises of 27 
cases of squamous cell carcinomas, 2 cases were of small cell carcinoma, 
1case of adenocarcinoma. Among this ,10 cases( 33.33%)  show increased 
expression of HER2 oncoprotein.  Gupta .et al group had total of 32 cases of 
parametrial extension and  among this 32 cases , 23 cases ( 71.88%)were  
positive for HER2/neu. 
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TABLE no 33:Comparison of HER2 expression in parametrial 
extension of carcinoma cervix in Gupta .et al and present study:          
Name of study Total cases HER2 positivity 
Gupta.et al 
(2009)
(95) 
32 23( 71.88%) 
Present study 30 10(33.33%) 
 
The both studies show increased HER2expression in parametrial 
extension cases. Compared to HER2 expression in lymphnode positive cases 
and parametrial extension, lymphnode positive cases showed increased 
positivity.      
There was a significant correlation between positive  HER2 
expression and higher clinical stage of presentation .HER2 expression  was 
significantly higher in lymph node positive cases  than in  lymphnode  
negative cases  .There  was also  significantly high expression in cases with 
parametrial involvement. In other study by Nidhi Gupta et al, there was 
positivity in adeno carcinoma and adenosquamous carcinoma. But  in 
present study , there was no positivity in adeno and adenosquamous 
carcinoma. In  contrast, there was positivity in small cell carcinoma of about 
33.33 % . Other than histological types, results correlate well with other 
similar studies. 
102 
 
     In the literature , there are reports in favour of increased expression of 
HER2 oncoprotein and also reports saying that there is only rare 
overexpression of HER2 oncoprotein. 
Thus , there are contradictory reports on expression of HER-2/neu  
and prognosis in various uterine lesions which may either be due to 
heterogeneity of lesions or technical problem with antigen retrieval. HER-
2/neu has a complex activation pathway and its expression is controlled not 
only by the degree of gene amplification but also by several other factors 
like gene receptor alteration and rate of gene transcription, which help in 
tyrosine kinase activation leading to cellular transformation.
 [96]
.Steroid 
hormones can also modulate gene expression by direct binding of hormone 
receptor complexes to specific DNA regulating sites.
 [97],[98]
 It is quite evident 
that modification in any of these factors can alter the over-expression of 
HER-2/neu, thus altering the positivity rates on immunostaining in various 
malignant neoplasms including carcinoma cervix. Whether or not these 
factors are associated with the prognosis, is a matter of further investigation. 
 
  
103 
 
SUMMARY 
1. HER2/neu expression in invasive cervical carcinoma  is 17% 
2. For higher clinical stage of carcinoma cervix, HER2/neu expression is 
more   (stage III carcinoma-50%).   
3. HER2/neu expression is more in  carcinoma cervix cases with 
lymphnode metstatic cases(55.5%) and cases with parametrial 
extension cases(33.33%). 
4. HER2/neu expression is more in moderately differentiated carcinoma. 
poorly differentiated carcinoma of cervix(25%) and Small cell 
carcinoma of cervix  ( 33.33%). 
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CONCLUSION 
1. This study shows  HER2/neu  expression in cervical carcinoma  
correlates with higher clinical stage (stage III ). 
2. HER 2 /neu expression correlates with Histological types of carcinoma 
Cervix. 
3. HER2/neu expression in carcinoma cervix  correlates with lymphnode 
metastasis and with parametrial extension .  
4. Expression of HER2/neu in carcinoma cervix, in this study is lower , 
when compared to other similar studies. Hence further studies on various 
factors associated with HER2 expression  and its positivity rates in  
various  subtypes  and  their prognostic significance are needed. 
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ANNEXURE-I 
PROFORMA 
 
Case number  :  
Name    : 
Age    : 
Sex    : 
HPE number  :  
IP number   : 
Clinical history : 
Risk factors, if any  : 
Clinical diagnosis   : 
Imaging    : 
Previous HPE report : 
Nature of specimen  : cervix biopsies, or total abdominal hysterectomies 
GROSS  : 
Size of the tumor in hysterectomy specimen, total nodes dissected, parametrial  
extension  
 
 
  
MICROSCOPY 
Histological type : 
Histological grade : well differentiated, moderately differentiated, and poorly  
                                 differentiated carcinoma of squamous cell carcinoma 
Associated findings : 
Total number of nodes dissected: Number of nodes involved: 
Parametrial extension, Distant metastasis 
FIGO staging   : 
IMMUNOHISTOCHEMISTRY 
HER2/neu  score: 1+,2+,3+, negative 
 
 
 
 
 
 
 
 
ANNEXURE -II 
WHO CLASSIFICATION 
 EPITHELIAL TUMORS: 
 Squamous tumors and precursors 
Squamous cell carcinoma, not otherwise specified        
 Keratinising 
 Non keratinising 
 Basaloid  
 Verrucous  
 Warty  
 Papillary 
 Lymphoepithelioma 
 Squamotransistional  
Early invasive ( microinvasive) squamous cell carcinoma 
          Squamous intraepithelial neoplasia 
 Cervical intraepithelial neoplasia(CIN3) 
 Squamous cell carcinoma in situ 
          Benign squamous cell lesions 
 Condyloma accuminatum 
 Squamous papilloma 
 Fibroepithelial polyp 
Glandular tumors and precursors 
          Adenocarcinoma  
Mucinous adenocarcinoma 
 Endocervical 
 Intestinal 
 Signet-ring cell 
 Minimal deviation 
 Villoglandular 
 Endometrioid adenocarcinoma 
 Clear cell adenocarcinoma 
 Serous adenocarcinoma 
 Mesonephric adenocarcinoma 
          Early invasive adenocarcinoma  
Adenocarcinoma in situ                
Glandular dysplasia 
Benign glandular lesions 
 Mullerian papilloma 
 Endocervical polyp 
Other epithelial tumors 
          Adenosquamous carcinoma 
 Glassy cell carcinoma variant 
Adenoid cystic carcinoma  
         Adenoid  basal carcinoma 
          Neuroendocrine tumors 
 Carcnoid 
 Atypical carcinoid 
 Small cell carcinoma 
 Large cell neuroendocrine carcinoma 
        Undifferentiated carcinoma      
MESENCHYMAL TUMORS AND TUMOR LIKE CONDITIONS 
          Leiomyosarcoma 
          Endometrioid stromal sarcoma, low grade 
          Undifferentiated endocervical sarcoma 
          Sarcoma botryoides 
          Alveolar soft part sarcoma 
          Angiosarcoma 
          Malignant peripheral nerve sheath tumor 
          Leiomyoma 
Genital rhabdomyoma 
Postperative spindle cell nodule  
MIXED EPITHELIAL AND MESENHYMAL LESIONS 
 Carcinomasarcoma 
 Adenosarcoma 
 Wilms tumor 
 Adenofibroma 
 Adenomyoma 
Melanocytic tumors 
MISCELLANEOUS TUMORS 
         Tumors of germ cell type 
 Yolk sac tumor 
 Dermoid cyst 
 Mature cystic teratoma 
Lymphoid hematopoeitic tumors 
Secondary tumors 
   
 
 
 
 
                 
ANNEXURE III 
Staging is done by FIGO staging(94) 
 
Stage I 
 
Cervical carcinoma confined to uterus (extension to the corpus 
should be disregarded) 
Stage IA 
 
Invasive carcinoma diagnosed only by microscopy; all 
macroscopically visible lesions, even with superficial invasion, are 
stage IB 
Stage IA1 Stromal invasion no greater than 3.0 mm in depth and 7.0 mm or 
less in horizontal spread 
Stage IA2 Stromal invasion more than 3.0 mm and not more than 5.0 mm 
with a horizontal spread of 7.0 mm or less 
Stage IB Clinically visible lesion confined to the cervix or microscopic 
lesion greater than IA2a 
Stage IB1 Clinically visible lesion 4.0 cm or less in greatest dimension 
Stage IB2 Clinically visible lesion more than 4.0 cm in greatest dimension 
Stage II Tumor invades beyond the uterus but not to pelvic wall or to 
lower third of the vagina 
Stage IIA Without parametrial invasion 
Stage IIA1 Clinically visible lesion _4.0 cm in greatestdimension 
Stage IIA2 Clinically visible lesion >4 cm in greatest dimension 
Stage IIB With parametrial invasion 
Stage III Tumor extends to the pelvic wall and/or involves lower third of 
vagina and/or causes hydronephrosis or nonfunctioning kidney 
Stage IIIA Tumor involves lower third of vagina with no extension to pelvic 
wall 
Stage IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or  
nonfunctioning kidney 
Stage IV The carcinoma has extended beyond the true pelvis or has 
involved (biopsy proven) the mucosa of the bladder or rectum. A 
bullous edema, as such, does not permit a case to be allotted to 
stage IV 
Stage IVA Spread of the growth to adjacent organs 
Stage IVB Spread to distant organs 
 
 
 
 
ANNEXURE IV 
HAEMATOXYLIN & EOSIN STAINING TECHNIQUE
[90] 
PREPARATION OF HAEMATOXYLIN SOLUTION: 
Haematoxylin                                                   2. 5gm 
Mercuric oxide                                                  1.25gm 
Potassium alum                                                 50gm 
Absolute ethyl alcohol                                      25ml 
Sodium iodate                                                   0.5gm      
Distilled water                                                  500ml 
PROCEDURE: 
Potassium alum, 50gm is dissolved in 500ml of distilled water by heating 
and shaking at 600 C. Add solution of 2.5gm of Haematoxylin in 25ml of absolute 
ethyl alcohol and bring rapidly to boil. When it begins to boil, remove from flame 
and add 1.25gm of mercuric oxide or sodium iodate. Mix by swirling gently. 
PREPARATION OF EOSIN SOLUTION: 
Eosin Y                                                              1gm 
95% Ethanol                                                      80ml 
Glacial Acetic acid                                            0.2ml 
Distilled water        20ml 
  
PROCEDURE: 
Dissolve 1gm Eosin Y in 20ml of distilled water and add 80ml of 95% 
etanol and 0.2ml of glacial acetic acid. 
STAINING PROCEDURE: 
1.Xylene 3 changes-2mins each. 
2.90%, 80%, 70% alcohol-10 dips each. 
3. Bring sections to water. 
4. Harris Haematoxylin-15 minutes. 
5. Rinse in tap water. 
6. Differentiate in 1% acid alcohol. 
7. Rinse in tap water. 
8. Lithium carbonate 0.5%- until blue. 
9. Tap water wash. 
10. Eosin-15secs to 2mins depending on age of Eosin. 
11. Rinse in tap water. 
12. Dehydrate in 95% alcohol. 
13. Absolute alcohol-3 changes-10 dips each. 
14. Xylene 2 changes-10 dips. 
15. Mount in DPX mountant. 
RESULTS: 
Nuclei- Blue 
Cytoplasm, RBCs, Keratin- Pink 
Eosinophil granules- Orange red 
  
ANNEXURE V 
 
KEY FOR MASTER CHART: 
1    - Squamous cell carcinoma, well differentiated 
2    - Squamous cell carcinoma, moderately differentiated 
3    - Squamous cell carcinoma, poorly differentiated 
4-   - Small cell carcinoma 
5    - Adenocarcinoma 
6    - Adenosquamous carcinoma 
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